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Summary of the MRP Portfolio 
This thesis examines psychological effects of MDMA. It consists of two sections.  
Section A is a systematic literature review investigating the psychological 
effects of MDMA on emotional processes and pro-social behaviours. It critically 
reviews the empirical studies investigating emotional and pro-social effects of 
MDMA in both recreational users and in a therapeutic setting. Limitations and future 
research directions are discussed. 
Section B is an empirical paper reporting the findings from an online-based 
quantitative study exploring a range of individual and environmental factors and their 
role in shaping the psychological effects of 3,4-methylenedioxmethamphetamine 
(MDMA), as well as their function in reducing the risk of the drug abuse. The results 
and implications, as well as future research directions, are discussed.  
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Abstract 
Although there are existing reviews published on psychological effects of MDMA, 
none have specifically explored the effects of MDMA on emotional processes and 
pro-social behaviour. The current review aims to critique the literature on emotional 
and pro-social effects of MDMA in both recreational users and in a therapeutic 
setting.  
Searches were conducted on PsycInfo, PubMed, Medline, and Google Scholar for 
peer-reviewed articles to identify quantitative studies targeting the effects of MDMA 
on emotions and pro-social behaviour, including recreational and therapeutic use of 
MDMA.  
Twenty-four studies were identified. Overall, the studies supported the hypotheses 
that MDMA alters emotional process by increasing positive emotions and diminishing 
negative emotions, and it increases sociability and pro-social behaviours by elevating 
the perceived value of social interactions and intimacy with others. MDMA was 
found to increase emotional empathy, whereas the relationship between MDMA and 
both cognitive empathy and emotional intelligence remains unclear.  
The preliminary studies presented provide preliminary evidence that MDMA may be 
successful in treating treatment-resistant PTSD. Further research addressing both 
recreational and therapeutic use of MDMA is warranted.  
 
Keywords: MDMA (Ecstasy), psychological effects, emotions, pro-social effects.  
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Introduction 
MDMA 
MDMA (3,4-methylenedioxmethamphetamine) is a synthetic psychoactive 
drug better known by its street name ‘ecstasy’ (Weir, 2000). MDMA is one of the 
most popular recreational drugs in the United Kingdom (UK, Home Office, 2012; 
Uosukainen, Tacke, & Winstock, 2015). Similar trends were reported across Europe, 
as well as the United States (US) and Australia (Thomas et al., 2012; United Nations 
Office on Drugs and Crime, 2012).  
MDMA was first synthesised in 1912 by German pharmaceutical company 
Merck and was briefly tested on animals by the American Army as a potential 
brainwashing agent in 1953 (Holland, 2001). Two decades later in 1976, Sasha 
Shulgin, a chemist from the US, synthesized MDMA in his own laboratory and 
introduced the drug to a group of psychotherapists. MDMA was subsequently used in 
underground psychotherapeutic work in the late seventies and early eighties, with 
very promising outcomes (Greer & Tolbert, 1986). However, in the early eighties, 
MDMA was leaked from the medical community and became a popular recreational 
drug, which led to Drug Enforcement Administration (DEA) declare MDMA as a 
schedule I drug in 1985. This put an end to the psychotherapeutic use of MDMA due 
to its illegal status. Despite the government’s attempts to cease the use, recreational 
use of the drug spread over to Europe and its popularity has been well documented 
since (United Nations Office on Drugs and Crime, 2012). 
Recreational Use of MDMA 
 Recreational use of ecstasy, in particular at dance clubs, is a cultural 
phenomenon, which initiated in the late eighties. In the UK, those taking part in the 
use of ecstasy at dance clubs were referred to as the ‘Chemical Generation’ 
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(Hammersley, Khan, & Ditton, 2002). Rave parties involve all-night dancing fuelled 
by the stimulants, predominantly ecstasy, which is referred to as a ‘club drug’ (Weir, 
2000). The popularity of ecstasy as a recreational drug has remained stable over the 
past three decades (United Nations Office on Drugs and Crime, 2012). Among young 
people aged 16-24, the use of ecstasy in the UK has increased since 2013/14 from 3.9 
per cent to 5.4 per cent, although this figure increases by further 25 per cent when the 
respondents are attending nightclubs on a regular basis (Home Office, 2015). There 
are several issues regarding the widespread use of MDMA, which are highlighted 
below.  
 One of the main issues in relation to the recreational use of ecstasy is its purity 
and the exact content of the pills available on the underground market (Cole, Bailey, 
Sumnall, Wagstaff, & King, 2002; Parrott, 2004). Research shows variation in 
MDMA content of ecstasy tablets and presence of other adulterants, which poses 
serious methodological problems in research of this substance (Vogels et al., 2009). A 
large-scale study in the Netherlands (Brunt, Koeter, Niesink, & van den Brink, 2012) 
reported higher levels of subjective adverse effects as a result of consuming ecstasy 
tablets containing other drugs apart from MDMA.  
MDMA was classified as a Class A drug in the US and the UK in 1985 
implying it’s high risk of addictive abuse potential and the lack of medical use 
(Holland, 2001). However, there is a lack of evidence in the literature for an MDMA 
dependence syndrome similar to the one observed in alcohol or opioids users 
(Degenhardt, Bruno, & Topp, 2010). Although increased tolerance as well as 
psychological aspects of dependence seem to be more prominent among MDMA 
users, physical characteristics such as withdrawal are less common (Degenhardt et al., 
2010; Degenhardt & Hall, 2012; White et al., 2006). Furthermore, a relatively small 
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percentage of MDMA users report problems with their use, or seek treatment 
(Degenhardt et al., 2010). A recent international study on harms and benefits 
associated with psychoactive substances considered MDMA use less harmful and 
more beneficial than the majority of other substances studied, including alcohol, 
Tobacco and benzodiazepines (Morgan, Noronha, Muetzelfeldt, Fielding, & Curran, 
2013).  
MDMA has been in the public spotlight for the past 30 years due to its 
capability to become a therapeutic tool for psychotherapy on one side, and its 
potentially neurotoxic effect in humans, on the other (Chabrol, 2013; Holland, 2001; 
Sessa, 2007). Research on neurotoxicity of MDMA in humans raise concerns that it 
may lead to both short- and long-term adverse effects on cognitive functioning. In 
particular, these have been argued to include verbal memory deficits (Verheyden, 
Henry, & Curran, 2003) and relatively slow processing speeds (e.g. Halpern et al., 
2011), and a range of executive impairments, including spatial working memory (e.g. 
Hanson, K. L., Luciana, 2004), verbal fluency (e.g. Bhattachary & Powell, 2001; Fox 
et al., 2002; Heffernan, Ling, & Scholey, 2001). On the contrary, other studies report 
the lack of deficits (e.g. Back-Madruga et al., 2003; Gouzoulis-Mayfrank, Thimm, 
Rezk, Hensen, & Daumann, 2003; Vollenweider, Gamma, Liechti, & Huber, 1998).  
MDMA as a Therapeutic Agent 
 Entactogens are drugs that have been used to facilitate the psychotherapeutic 
process by enabling patients to access and process often painful and repressed 
emotional material (Nichols, 1986). MDMA was classified as an entactogen due to 
effects which Nichols (1985) described as intensely emotional and argued allows 
people to establish a deeper connection with their true self. In  2001, Metzner and 
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Adamson proposed the alternative name ‘Empathogens’ to highlight the drug’s ability 
to enhance interpersonal relationships and feelings of empathy.  
 From the perspective of potential for clinical use as an entactogen, MDMA 
possesses unique effects on the human brain. Firstly, it acts as a mood enhancer due to 
its euphoric effects (Sessa & Nutt, 2015). Secondly, MDMA is the only anxiolytic 
drug without a sedative effect, which may prove to be particularly useful in the 
treatment of anxiety disorders (Sessa & Nutt, 2015). Thirdly, MDMA reduces 
defensiveness and enables bonding with others as well as improving social 
interactions and emotional regulation (Johansen & Krebs, 2009). All of the above 
characteristics are argued to make MDMA well-suited to act as a therapeutic agent 
(Parrott, 2007; Sessa, 2007). 
PTSD Treatment  
 PTSD is a deliberating condition characterised by intrusive re-living of the 
traumatic events, associated with intense anxiety and excessive arousal as well as 
avoidance of any stimuli that might trigger the fear response, often leading to severe 
difficulties managing everyday life (APA, 2013). PTSD develops as a result of 
experiencing a life-threatening event, in particular among survivors of sexual abuse, 
war veterans and those who endured severe accidents.  
 Cognitive-behavioural therapy (CBT) provided a useful model for  
development and treatment of PTSD (Ehlers & Clark, 2000). The model implies that 
PTSD becomes persistent when the traumatic event and its squeal is experienced as a 
current threat causing distortions in processing the traumatic memory, which leaves it 
poorly integrated within the autobiographical memory store (Ehlers & Clark, 2000). 
The prefrontal cortex and the amygdala form an emotional regulation circuit, and 
have been found central in maintenance of the PTSD symptoms. People with PTSD 
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show dysfunctional connectivity in these regions associated with increased activity of 
the amygdala, which is a part of the brain responsible for the fear response. Prolonged 
exposure to safe but fear evoking triggers is one of the most commonly used 
techniques for treatment of PTSD (Bradley et al., 2005; Roth & Fonagy, 2005). This 
technique can lead to strengthening the connectivity in the prefrontal cortex and the 
inhibition of amygdala-induced fear responses (Amoroso, 2015; Krebs & Johansen, 
2012). This results in improvement of emotional regulation and facilitates 
incorporation of corrective information into the trauma memory in the hippocampus 
(Amoroso, 2015).  
Although, there is robust evidence that CBT is a safe and effective treatment 
for PTSD, up to 50% of patients undergoing this form of therapy do not improve 
(Kar, 2011). High rates of nonresponse to treatment and dropouts seem to be 
associated with greater severity of PTSD symptoms, in particular avoidance and 
hyperarousal as well as comorbid mental health problems such as depression and 
borderline personality disorder, and impaired social functioning (Kar, 2011). These 
factors suggest that CBT might not always be an acceptable form of treatment for 
more acutely distressed clients, therefore, implying the need for a more tolerable 
treatment alternative.  
 Some preliminary studies have suggested that MDMA may be effectively 
employed in treatment of PTSD (Amoroso, 2015; Johansen & Krebs, 2009). Imaging 
studies in healthy volunteers showed that MDMA reduced activity of amygdala and 
hippocampus, (Carhart-Harris et al., 2013; Gamma et al., 2000), which might be 
responsible for reduction in anxiety response to a recollection of traumatic content. In 
a clinical setting, MDMA has been experimentally observed to produce a state of 
improved insight, allowing non-threatening exploration of painful and repressed 
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memories associated with traumatic past experiences, by ‘inhibiting the subjective 
fear response to an emotional threat’ (Greer & Tolbert, 1998, p. 371).  
Lowering of the anxiety response while engaging in a compassionate relating to the 
traumatic incidents during the MDMA-assisted psychotherapy session, seems to be 
instrumental in processing traumatic memories and allowing emotional learning 
(Amoroso, 2015).  
The Effects of MDMA on Emotions and Pro-social Behaviour 
 Pro-social effects of MDMA, such as sociability, interpersonal closeness and 
feelings of empathy for others; and emotional effects described as improved mood, 
and feelings of euphoria and well-being, were reported by Sumnall, Cole and Jerome 
(2006) as the main reason for its use.  
 The empathy construct incorporates both cognitive and emotional elements 
(Blair, 2005). Cognitive empathy can be described as one’s ability to identify 
emotional states in others, whereas the emotional aspect of empathy refers to the 
sensations and feelings as a response to feelings perceived in another person (Blair, 
2005). 
 Emotional and pro-social effects of MDMA seem to contribute to both its 
recreational and therapeutic uses, although relatively little is known to date about the 
basic emotional processes responsible for these specific effects. MDMA may 
facilitate pro-social effects by directly producing positive emotional and pro-social 
subjective states, or by enhancing responses to positive emotions and diminishing 
responses to negative emotions (Hysek, Domes, & Liechti, 2012).  
 Developing a better understanding of the emotional and behavioural 
mechanisms by which MDMA is thought to produce these pro-social and emotional 
effects may be useful in expanding our understanding of recreational use as well as 
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the mechanisms of the therapeutic potential of the drug. Research on this topic has 
been limited by the legal status of MDMA as well as the methodological difficulties 
in assessing these effects (Kirkpatrick, Delton, Robertson, & de Wit, 2015). However, 
over the past decade, a considerable number of studies investigating emotional and 
pro-social effects of MDMA have been published.  
 
Aims and Objectives of the Current Review 
Aims.  The primary aim of this review is to examine and summarise the 
existing research on emotional and pro-social effects of MDMA on humans. 
Furthermore, the review aims to provide a methodological critique of the literature 
and considers both research and clinical implications. 
Scope.  Although there are existing reviews published on psychological 
effects of MDMA, none specifically explored emotional and pro-social effects of the 
drug on humans. For example, most reviews address a wide range of short-term and 
long-term subjective effects of MDMA (Baylen & Rosenberg, 2006; Burgess, 
O’Donohoe, & Gill, 2000; Noller, 2009; Parrott, 2001; Vollenweider, Liechti, 
Gamma, Greer, & Geyer, 2002). Other reviews focus on neurotoxicity and adverse 
physical and mental health problems related to MDMA use in humans (Burgess et al., 
2000; Gowing, Henry-Edwards, Irvine, & Ali, 2002; McGuire, 2000; Morgan, 2000; 
Parrott, 2002; Rivas-Vazquez & Delgado, 2002; Soar, Turner, & Parrott, 2001). None 
of the previous reviews investigated emotional effects of MDMA in both recreational 
users and in a therapeutic setting to allow a more comprehensive comparison of the 
effects.  
Since this review focuses on emotional and pro-social effects of MDMA, only 
studies looking at emotional states and pro-social behaviours were selected. It is 
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beyond the scope of this review to investigate mental health problems related to 
MDMA use such as depression or anxiety (e.g. Daumann et al., 2004; Taurah, 
Chandler, & Sanders, 2014) as well as studies addressing cognitive deficits including 
memory problems and disinhibition (Gouzoulis-Mayfrank et al., 2000; e.g. Zakzanis, 
Young, & Campbell, 2003).  
Method 
Literature Search 
This review was based on a search of four online databases: PsycInfo, 
PubMed, Medline, and Google Scholar. Searches for peer-reviewed articles published 
before 1st December 2015 (last database search) were conducted. A manual search of 
the references of relevant papers was also carried out.  
The following search terms were selected: ‘MDMA or 3,4-
methylenedioxmethamphetamine or ecstasy or Molly or Adam’ and ‘emotion or 
emotion(al) processing or pro(-)social behaviour or sociability’. The search strategy 
was limited to articles published in English.  
All papers included in this review met all of the following criteria:  
1. The study focused primarily on exploring the effects of MDMA on emotions and 
pro-social behaviour.  
2. The participants were recreational MDMA users or used MDMA as a therapeutic 
agent.  
3. The study included at least one measure of emotional effects of MDMA or pro-
social behaviour. 
4. The study employed a quantitative methodology.  
Based on titles and abstracts, a subset of 854 articles was screened, resulting in 
the selection of 89 manuscripts for a full-text review. The selected articles were 
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reviewed using the inclusion and exclusion criteria (see Figure 1 for search 
procedures). The final step of the screening identified 24 relevant studies. Refer to  
Appendix 1 for further details. 
	
Figure	1.	Flow	Diagram	of	Search	(PRISMA,	Moher,	Liberati,	Tetzlaff,	Altman,	&	
The	PRISMA	Group,	2009)	
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Structure of this Review 
The structure of this review was organised to critically appraise psychological 
effects of MDMA in two types of setting; recreation and therapeutic. In the 
recreational setting group, there were 12 randomised controlled trials (RCTs), four 
naturalistic studies and three correlational studies. The therapeutic setting group 
included three RCTs (see Appendix 1 for summary tables).  
The RCTs and naturalistic studies were critiqued according to the Critical 
Appraisal Skills Programme for reporting RCT (CASP, 2013), and correlational trials 
were evaluated according to the CASP guidelines for reporting Case Control Trials 
(Critical Appraisal Skills Programme (CASP, 2013a).  
The following section of the review presents the general findings. This is 
followed by discussion of results, and consideration of research and clinical 
implications. 
Results 
Psychological Effects of MDMA in Recreational Users 
Randomised controlled trials.   This review will start with an exploration of 
the experimental literature, which has been divided into three sub-categories. Firstly, 
the effects of MDMA on positive and negative emotions are discussed. This is 
followed by an examination of the effects of the drug on sociability and pro-social 
behaviour, after which trials investigating the effects of MDMA on empathy are 
reviewed. All of the studies took place in a laboratory environment, where a dose of 
chemically pure MDMA was administered to participants by medical staff. The doses 
of MDMA ranged between 0.5 mg/kg to 1.5 mg/kg. The studies employed a 
randomised double-blind, within-participants design (see Appendix 1 for more 
details).  
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Positive and negative emotions.  Eight RCT studies examined the acute 
effects of MDMA on the intensity of emotional experiences as well as the ability to 
identify emotions in others (Baggott, Kirkpatrick, Bedi, & de Wit, 2015; Bedi, 
Hyman, & de Wit, 2010; Bedi, Phan, Angstadt, & de Wit, 2009; Carhart-Harris et al., 
2013; Hysek et al., 2012; Hysek, Schmid, et al., 2014; Hysek, Simmler, et al., 2014). 
See Table 1 in Appendix 1 for further details.   
Results from all the reviewed trials support the hypotheses that MDMA would 
increase subjective positive emotions and decrease subjective negative emotions in 
their participants, as well as improve their ability to identify positive emotions in 
others. The emotional effects of MDMA were measured through self-reported ratings 
of affective states. The ability to recognise emotions in others were assessed by 
completing standardised images depicting emotional facial expressions and, in some 
cases, also vocal cues.  
With regards to the ability to recognise negative emotions in others, the results 
are inconclusive. Two studies conducted by the same research group (Bedi et al., 
2010, 2009) reported that MDMA decreased accurate identification of threat-related 
signals in others  (i.e. the ability to recognise angry faces). Four other studies 
identified that the ability to identify all negative emotions in others such as anger, fear 
and sadness, was impaired (Hysek et al., 2012; Hysek, Schmid, et al., 2014; Hysek, 
Simmler, et al., 2014; Kirkpatrick, Lee, Wardle, Jacob, & de Wit, 2014). Hysek, 
Schmid, et al. (2014), reported gender differences with female participants displaying 
greater difficulty identifying negative emotions in others in comparison to male 
participants.  
In a study by Baggott, Kirkpatrick, Bedi, and de Wit, (2015), participants 
completed a standardised talking task during which they discussed a significant 
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relationship, for example with a family member or a friend. They found that MDMA 
increased the use of words relating to both positive and negative emotions. Finally, in 
a British study (Carhart-Harris et al., 2013), participants’ recall of most positive and 
negative autobiographical memories was assessed under the influence of MDMA. The 
results supported their hypothesis that MDMA use would result in participants rating 
their favourite memories as more positive and emotionally intense, and rating their 
most disliked memories as less negative.  
Sociability and pro-social behaviour.  Six RCTs measured the acute effects of 
MDMA on sociability and pro-social behaviour (Bedi et al., 2009; Frye, Wardle, 
Norman, & de Wit, 2014; Kirkpatrick & de Wit, 2015; Kirkpatrick et al., 2015, 2014; 
Wardle, Kirkpatrick, & de Wit, 2014). Refer to Table 1 in Appendix 1 for more 
details. All studies reported that MDMA had a positive impact on sociability and 
increased pro-social behaviour. The studies employed self-report measures of 
sociability.  
MDMA was also found to enhance responses to rewarding social signals (Bedi 
et al., 2009) and decrease the perception of social rejection in a virtual social 
simulation task called ‘Cyberball’ (Frye et al., 2014). Another study suggested that 
MDMA increases a level of generosity, measured by a task in which participants 
make decisions whether they or someone else receives money (Kirkpatrick et al., 
2015). However, this effect seemed to be mediated by the social proximity of the 
relationship (Kirkpatrick et al., 2015).  
Three other studies run by the same research group also support the pro-social 
effect of MDMA. The drug was found to increase the desire to be with others 
(Kirkpatrick et al., 2014), and increased positive ratings of positive social pictures 
while reducing the positive ratings of non-social positive pictures (Wardle, 
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Kirkpatrick, & de Wit, 2014), suggesting that MDMA increases the relative value of 
social interactions and intimacy with other people. The third study was the first to 
investigate the role of the social contact and its impact on the effects of MDMA 
(Kirkpatrick & de Wit, 2015). Social contact with other participants (who were also 
currently experiencing effects of MDMA), in comparison to the contact with a 
research assistant or a solitary condition was found to reinforce some of the subjective 
and physiological effects of MDMA. Furthermore, the study found that MDMA 
increased the frequency of social interactions and self-reported perceived 
attractiveness of a person in the room (Kirkpatrick & de Wit, 2015). This study 
supported the role of the social context in shaping certain effects of MDMA.  
 Empathy.  Three studies investigated how acute effects of MDMA might 
affect empathy (Bedi et al., 2010; Hysek, Schmid, et al., 2014; Kuypers et al., 2014; 
see Table 1 in Appendix 1). All three studies supported the hypothesis that MDMA 
increases empathy, with Bedi et al. (2010) reporting it increased self-rated 
empathogenic feelings.  
Two studies measured emotional empathy and cognitive empathy through a 
set of standardised tasks, finding emotional empathy enhanced in the MDMA 
conditions. The results of the impact of the drug on cognitive empathy are 
inconclusive. Kuypers et al., 2014 reported that MDMA did not increase cognitive 
empathy as well as trust and reciprocity. However, Hysek, Schmid, et al. (2014), 
claimed that MDMA increased cognitive empathy but only among male participants, 
whereas there was no significant increase among female participants.  
Overall methodological critique.  Overall, all of the RCTs presented in this review 
were of satisfactory standards. However, there were a number of methodological 
issues. 
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The studies used randomised double-blind crossover (within-participants) 
design, which partially addresses the issue of systematic differences between the two 
conditions. However, one of the main issues in the majority of the trials is the lack of 
an active control group. Only four trials (Bedi, Hyman, & de Wit, 2010; Hysek, 
Schmid, et al., 2014; Kirkpatrick et al., 2014; Kuypers et al., 2014) used active control 
groups: methamphetamine, Ritalin, intranasal oxytocin, and pindolol, respectively. 
The rest of the trials used only non-active placebo, which might create certain issues 
of participants’ bias due to distinctive, perceptible and strong effects of MDMA 
therefore making a truly double-blinded design difficult to achieve. Both participants 
and researchers were likely to be able to tell whether someone is under the influence 
of MDMA compared to a non-active placebo.  
Another major methodological issue that needs elaborating on is the relatively 
poor ecological validity of the studies performed in the laboratory conditions. This 
seems to be a particular problem with regards to assessing ability to recognise 
emotions of others based on a standardised set of pictures of human’s faces. Similarly, 
assessing the levels of pro-social behaviour and empathy based on standardised tasks 
might be far removed from participants’ social context.  
Furthermore, the majority of the studies did control for a gender bias, having 
between 50% to 78% of male participants. This seems to be the prominent issue with 
regards to the generalizability of the findings to the female population. Similarly, 
there was a large variability among studies with regards to the doses of MDMA 
administered to participants. This makes it difficult to compare the results between 
studies as certain pro-social and emotional effects might be dose-dependent. For 
example, one study (Kirkpatrick et al., 2014) found that pro-social effects of MDMA 
were prominent at a higher dose 1.5mg / kg but not at a lower dose of .75mg/kg.  
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 Naturalistic studies. 
Emotion recognition, sociability and self-compassion.  This review will now present 
the evidence from naturalistic studies and a pseudo-experimental study (refer to Table 
2 in Appendix 1 for more details).  
One study (Yip & Lee, 2006) applied pseudo-experimental design to 
investigate long-term effects of ‘ecstasy’ on emotion recognition. Three studies 
(Hoshi, Bisla, & Curran, 2004; Kamboj et al., 2015; Stewart et al., 2014) applied 
naturalistic design to investigate the acute effects of MDMA on emotion recognition, 
sociability and self-compassion.  
 Yip and Lee (2006) completed pseudo-experimental, between-participants, 
non-randomised design. They compared 100 abstinent ‘ecstasy’ users with 100 
matched non-users. Participants took part in an adapted version of a facial emotion 
recognition test (Matsumoto and Ekman’s Japanese and Caucasian facial expressions 
of emotion, Biehl et al., 1997), and a test measuring prosodic emotion recognition, 
developed by the authors of the study (Yip & Lee, 2006). Findings suggest that 
emotion recognition among abstinent ‘ecstasy’ users was impaired compared with 
non-users’ emotion recognition. The findings were only related to the ability to 
recognise sadness and disgust, leaving other types of emotion recognition intact (i.e. 
happiness, anger, surprise and fear). Furthermore, the findings suggest that the 
cumulative number of ecstasy tablets previously taken might be a stronger predictor 
of impaired recognition of sadness and disgust rather than the length of abstinence 
from ‘ecstasy’. However, the authors did not present enough information on the 
duration of time since the participants used ‘ecstasy’ or relevant details on the pattern 
of drug use.  
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 Hoshi et al. (2004), used an independent group, repeated measures design to 
compare recreational ‘ecstasy’ users  (n = 16) and non-drug users (n = 21) at the time 
of ecstasy use in a dance club (ecstasy users) and four days later, when some users 
experience serotonin depletion and related mood disturbances (Parrott & Lasky, 
1998). All participants completed measures of drug use, mood, aggression, 
impulsivity and subjective effects of the drug, and took part in a standardised facial 
expression recognition task. ‘Ecstasy’ users were better at correctly identifying fearful 
facial expressions and presented lower levels of self-reported aggression at the time of 
the drug use. However, this was not consistent on day four where the control group 
was more accurate in identifying fearful expressions and ‘ecstasy’ users presented 
higher levels of aggression. Diminished fear recognition on day four was positively 
correlated with the number of years of ecstasy use and a number of ecstasy tablets 
taken on day one.   
Stewart et al. (2014) used the same design as described in the previous study, 
where 17 ‘ecstasy’ users were compared with a control group of non-drug users (n = 
22) at two points in time: on the night of drug use at participant’s homes, and three 
days later. Participants were asked to rate the trustworthiness of 66 faces, to carry out 
three co-operative behaviour tasks and to complete mood self-ratings and a 
standardised measure of trait empathy. The results indicated that ecstasy increased the 
ratings of face trustworthiness and co-operative behaviour. On day three there were 
no group differences in ratings of trustworthiness and co-operative behaviour, 
suggesting that the group differences were associated with the acute effect of the 
drug. Overall, ecstasy users displayed higher levels of trait empathy than the controls.  
 Finally, a recent study by Kamboj et al. (2015) used a two-session, within-
participants design with a group of 20 ‘ecstasy’ users. Participants completed a range 
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of self-report questionnaires measuring mood and ecstasy-related subjective effects, 
attachment styles, and trait self-criticism and self-compassing scales. The measures 
were administered in participants’ homes at three points in time: before and after 
ecstasy consumption and after a completion of a guided compassionate imaginary 
exercise while still under the influence of the drug. Results revealed that ‘ecstasy’ on 
its own increased self-compassion and reduced self-criticism, however, the effects 
were even greater after the compassionate imaginary exercise.  
Overall methodological critique.  The studies described above brought a 
unique understanding of the effects of ‘ecstasy’ on emotional processes and were of a 
higher ecological validity, however, there are a number of methodological problems 
that need addressing.  
Firstly, two studies (Hoshi et al., 2004; Stewart et al., 2014) assessed ecstasy 
users at two points in time only: in the acute phase of ecstasy effects and in an ecstasy 
‘hangover’ state which was four and three days after the ecstasy use, respectively. The 
lack of a neutral baseline testing session as observed in the third study by Kamboj et 
al. (2015), did not allow for a clear comparison of the ecstasy effects.  On the 
contrary, Yip and Lee (2006) only collected the data at the time of abstinence of 
ecstasy without identifying the acute effects of ‘ecstasy’.  
 Another significant methodological issue apparent in all four studies is the 
lack of control over dose and purity of the substance referred to as ‘ecstasy’. It is 
difficult to predict the amount of MDMA contained in ecstasy tablets consumed by 
participants as well as consumption of other drugs before the testing session. Only 
one study (Hoshi et al., 2004) reported the number of tablets taken by participants 
during the study.  
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 Furthermore, neither participants nor researchers were blind to treatment, 
creating a potential source of bias. Similarly, the fact that participants were tested in 
their own homes (Kamboj et al., 2015; Stewart et al., 2014) and in a club (Hoshi et al., 
2004), might have increased expectancy of the drug effects, in particular, those related 
to empathy and pro-social behaviour. Apart from Yip and Lee’s study (2006), the 
remaining three had relatively small sample sizes and a large proportion of males 
along with the gender mismatch between the groups, which were also potential 
sources of bias. 
 Correlational studies. 
Emotional intelligence and emotion recognition and personality traits.  This review 
will now focus on evaluating the evidence from three correlational studies (Craig, 
Fisk, Montgomery, Murphy, & Wareing, 2010; Reay, Hamilton, Kennedy, & 
Scholey, 2006; ter Bogt, Engels, & Dubas, 2006).  See Table 3 in Appendix 1 for 
more details.  
 Reay et al. (2006), compared 15 polydrug ecstasy users with 15 non-ecstasy 
polydrug user controls. Participants completed a general drug questionnaire, 
emotional intelligence scale (Schutte et al., 1998) and the Tromso Social Intelligence 
Scale (Silvera, Martinussen, & Dahl, 2001) to evaluate emotional and social 
processing, respectively. The study found that ‘ecstasy’ polydrug users in comparison 
to non-ecstasy polydrug users, had worse outcomes on two subscales of social 
intelligence scale: social awareness and social skills, and also scored lower on the 
measure of emotional intelligence.     
A similar study by Craig et al. (2010), compared ‘ecstasy’ polydrug users (n = 
78) with cannabis-only users (n = 38) and non-drug users (n = 34). Participants 
completed a drug use questionnaire, Emotional Intelligence Measure (Schutte et al., 
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1998), and Mood adjective checklist (Matthews, Jones, & Chamberlain, 1990). The 
results indicated that ‘ecstasy’ users did not differ from non-users on measures of 
emotional intelligence. Furthermore, adverse mood effects associated with ecstasy use 
were associated with lower levels of emotional intelligence. On the contrary, higher 
levels of emotional intelligence were associated with ecstasy-related precautions used 
when using the drug such as monitoring fluid intake, taking rest breaks when dancing.
 The results of the two studies investigating emotional intelligence among 
polydrug ecstasy users are inconclusive. Both studies used the same measure of 
emotional intelligence (Schutte et al., 1998) and were carried out in the UK. Reay et 
al. (2006) used a very small sample size and reported significant differences in the 
levels of cannabis consumption between the groups. Even though the cannabis use 
was not directly related to emotional intelligence, it is conceivable that the interaction 
of the two drugs (ecstasy and cannabis) might have been responsible for the observed 
group differences; however, this was not empirically supported by either study.  
Finally, a large study by ter Bogt et al. (2006) compared a sample of 381 
MDMA users among which 170 were under the influence of MDMA when 
completing the survey, with a sample of party-goers who did not use MDMA (n = 
160) and a national sample of 265 non-hard drug using adults. Participants completed 
a drug use questionnaire, and a Dutch adaptation of Goldberg’s Big Five 
questionnaire (Goldberg, 1992), measuring five personality traits: agreeableness, 
extraversion, conscientiousness, emotional stability and openness. The results found 
MDMA use was associated with higher levels of extraversion and lower levels of 
conscientiousness. There were no significant differences in personality traits between 
people in the sample of MDMA users who were under the influence of MDMA while 
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filling out the questionnaires and sober MDMA users, which suggest that the acute 
effects of MDMA did not differentiate between the scores on the personality measure.  
Overall Methodological Critique.  There were several methodological problems 
identified in the studies described above. The correlational nature of the studies means 
that the results are uninformative with regards to the causality of the relationships 
and, therefore, should be interpreted cautiously. Reay et al. (2006) had a particularly 
small sample size, and all studies presented with an issue of gender imbalance with 
females participants being under-represented.  
The studies relied on self-report measures, which could be a potential source 
of bias with participants not disclosing accurate information. The majority of 
participants were poly-drug users, which is a very common problem in this area of 
research as there are limited ways of controlling for poly-drug use. Finally, there are 
significant issues around drug purity, dose and presence of adulterants, in particular 
among participants who use ecstasy pills. Since the majority of participants were 
poly-drug users it is very difficult to obtain information that would directly apply to 
this specific drug, creating potential confounding variables and questioning the 
validity of the results presented across the studies. All those factors make it very 
difficult to conclude that any evidence is directly related to MDMA use. 
Psychological Effects of MDMA in a Therapeutic Setting 
Randomised controlled trials.  The review will now move to focus onto the 
therapeutic setting of MDMA use and psychological effects resulting from 
preliminary MDMA-assisted therapy RCT studies published to date. Refer to Table 4 
in Appendix 1 for more details.   
All three trials (Bouso, Doblin, & Farré, 2008; Mithoefer et al., 2013; 
Mithoefer, Wagner, Mithoefer, Jerome, & Doblin, 2011; Oehen, Traber, Widmer, & 
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Schnyder, 2013), investigated the therapeutic potential of MDMA in treating chronic 
and treatment-resistant PTSD. MDMA was used as an adjunct to a course of short-
term psychotherapy and followed a treatment protocol described in the manual for 
MDMA-assisted psychotherapy in patients with PTSD (Mithoefer, 2013). Participants 
took part in non-drug preparatory psychotherapy sessions prior to the first MDMA 
experience, and the follow-up sessions, which were scheduled in-between MDMA-
assisted psychotherapy sessions to ensure the integration of the experiences from the 
MDMA sessions. The therapeutic approach during the MDMA sessions was generally 
non-directive, following and encouraging the naturally occurring recollection and 
processing of traumatic experiences.  
All studies used a double-blind, between-participants randomised and placebo-
controlled design. Bouso et al. (2008) completed a pilot study with only six 
participants, among which four were allocated to MDMA treatment group (50-75mg) 
and two were in a non-active placebo control group. The study was specifically for 
women with treatment-resistant PTSD secondary to a sexual assault. The study was 
planned to include five increasing doses of MDMA, ranging from 50 to 150 mg, in 29 
women. However, the study was prematurely terminated due to political pressure 
resulting in a very small group of six participants. Due to a small sample size, any 
statistical analysis comparing the two groups was not possible, allowing only for 
descriptive analysis. The study concluded that low doses of MDMA within the 
context of psychotherapy were found to be safe and the preliminary results have 
shown some promising signs of efficacy and reduced symptoms of PTSD.  
A second RCT was reported in two separate papers (Mithoefer et al., 2011) 
with some interesting long-term effects reported from the follow-up data (Mithoefer 
et al., 2013). Participants were women, who were randomly allocated into the 
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MDMA-assisted therapy group (n = 12) or non-active placebo (n = 8). MDMA was 
administered on two separate sessions in two doses, 125mg and 62.5mg respectively. 
The results indicated a significant reduction in clinical symptoms of PTSD in the 
MDMA group, in comparison to the placebo group. This was assessed by an 
independent clinician, who was blind to treatment condition, using a standardised 
measure (Clinician-Administered PTSD Scale, CAPS, Blake et al., 1995). The clinical 
response rate in the MDMA group was 83%, in comparison to 25% in the placebo 
group. Furthermore, a long-term follow-up reported that the participants maintained 
treatment gains at up to six years post-treatment.  
Finally, a RCT by Oehen et al. (2013) used a very similar design to the 
previous study but with an active placebo of the sub-therapeutic dose of MDMA (first 
dose: 25mg, second dose: 12.5mg). There were three MDMA sessions spread across 
the treatment period. There were eight participants, both male and female, in the 
MDMA group and four participants in the active placebo group. This study reported a 
lack of significant reduction in clinically rated CAPS scores (Blake et al., 1995) in the 
higher dose group compared to the active placebo group, but a significant reduction in 
a self-report measure of The Posttraumatic Diagnostic Scale (PDS; Foa, Cashman, 
Jaycox, & Perry, 1997). The follow-up data a year later showed further improvement 
on the CAPS scores in the MDMA group.  
Across all RCTs, where MDMA was administered in a clinical setting, it was 
found to be safe for participants. Participants’ heart rates and temperatures were 
measured regularly throughout the sessions to ensure safety. There were no drug-
related serious adverse events reported in any of the clinical studies.  
Overall Methodological Critique.  The RCTs described above present strengths 
such as a prospective double-blind design, the use of standardised outcome measures, 
PSYCHOLOGICAL EFFECTS OF MDMA 
 
 34 
and clearly defined inclusion and exclusion criteria. The majority of the participants 
were MDMA-naïve. This allowed for unique comparisons in terms of the drug 
effects. This kind of comparison is not usually observed in studies on recreational 
MDMA users.  
Furthermore, the use of a blinded, independent evaluator in all studies and 
well-matched baseline scores on the PTSD measure in two studies (Mithoefer et al., 
2011; Oehen et al., 2013) were also indisputable strengths of these innovative trials.  
The studies also have several limitations and although they provide promising 
results they should be interpreted very cautiously and only be considered as a 
preliminary step in the exploration of MDMA as an adjunct to psychotherapy for 
PTSD. Firstly, the studies had very small sample sizes and the majority of participants 
were female. Although small samples are relatively common in pilot studies, they are 
often unable to detect smaller effect sizes, which seemed likely among severe cases of 
prolonged and treatment-resistant PTSD.  
Secondly, the lack of active control groups in two trials, as well as the lack of 
assessment of the treatment fidelity in all trials, are the two major concerns with 
regards to the quality of the trials. Although, the studies provided information on 
therapists’ backgrounds and details on treatment protocols, there was no mentioning 
in the reports whether the therapists received regular supervision.  
Another significant weakness of the studies is the issue of transparency of the 
blinding to participants and therapists. It is quite likely that due to very strong and 
unique effects induced by MDMA, participants and therapists were no longer 
unaware of the group to which they had been assigned.   
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Discussion 
The aim of this review was to summarise and critically acclaim the existing 
evidence on emotional and pro-social effects of MDMA on humans, focusing on two 
types of the setting of the drug use; recreational and therapeutic.  
The RCTs using recreational users provided robust evidence that MDMA 
increases positive emotions while diminishing negative emotions. However, the 
evidence with regards to the ability to recognise negative emotions in others is mixed. 
All studies showed that the ability to recognise angry faces was impaired, with some 
also supporting the idea that identification of sadness and fear was also impaired ( e.g. 
Hysek, Schmid, et al., 2014; Hysek, Simmler, et al., 2014). The discrepancies 
between the studies might be due to the differences in study designs, in particular, the 
use of different tests measuring facial recognition across studies.  
The evidence from one pseudo-experimental study (Yip & Lee, 2006) and one 
naturalistic study (Hoshi et al., 2004) provided some contradicting results. Yip and 
Lee (2006), revealed a long-term emotion recognition impairment in abstinent ecstasy 
users. However, due to methodological weaknesses in the design of this study 
described earlier the results should be interpreted very cautiously. Hoshi et al. (2004), 
found that ‘ecstasy’ users were better at correctly identifying fearful facial 
expressions while under the influence of the drug but this effect diminished four days 
later.  
The contradicting evidence from naturalistic and pseudo-experimental studies 
might be possibly explained by the design weaknesses, in particular, the lack of 
control over the purity and dose of the drug consumed by the participants. Therefore, 
this evidence should be considered very carefully. There is also some preliminary 
evidence that MDMA may increase the emotional value of positive memories at the 
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same time as diminishing the negative value of most disliked memories (Hysek et al., 
2012). The studies have shown that MDMA increases sociability and pro-social 
behaviour by increasing the value of social interactions and intimacy with others. 
Similarly, MDMA increases emotional empathy, whereas the relationship between 
cognitive empathy and MDMA remains unclear. Hysek and Schmid, et al.’s 2014 
finding of gender differences in cognitive empathy and ability to recognise negative 
emotions in others was interesting as it suggested women might be more susceptible 
to the effects of MDMA compared to men. Gender differences in the effects of 
MDMA have been previously reported, for example, women were found to 
experience more acute subjective effects (Liechti, Gamma, & Vollenweider, 2001) as 
well as more negative long-term effects than men (Ogeil, Rajaratnam, & Broadbear, 
2013).  
Alongside the two other naturalistic trials (Hoshi et al., 2004; Stewart et al., 
2014), Kamboj et al.’s 2015 finding that increased self-compassion and reduced self-
criticism following MDMA use was further enhanced following a compassionate 
imaginary exercise provided a unique perspective on the potentially confounding 
variables that have not been addressed in the studies so far. None of the studies 
addressed the role of participants’ motivation and expectations of the drug on the 
effects reported by the participants, which was reported previously to have a 
significant impact on drug experiences (Zinberg, 1994). It is likely that the effects of 
the drug reported in a research laboratory will be somehow different to the effects of 
the drug reported in a recreational setting or a therapeutic setting. A study by 
Kirkpatrick and de Wit (2015) revealed that the social context, for example, the 
presence of another person under the influence of the drug, reinforces some of the 
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effects of MDMA. This appears to be a significant methodological omission in the 
majority of the studies reported in the literature to date.  
With regards to emotional intelligence in the ‘ecstasy’ users, the results of two 
correlational studies are inconclusive (Craig et al., 2010; Reay et al., 2006). The lack 
of clarity on this matter might be related to the poor control over the potential 
confounding variables related to the poly-drug use among recreational users.  
Finally, the three RCTs investigating the use of MDMA as an adjunct to 
psychotherapy revealed very promising results in treating treatment-resistant PTSD. 
This suggests that MDMA used in a therapeutic setting with the support of an 
experienced therapist might facilitate the emotional process, enabling participants to 
process traumatic material in a safer way. More importantly, the effects of the 
MDMA-assisted therapy seemed to have been long-lasting, with a low rate of relapse. 
Although, the results are very encouraging, the small sample sizes in these pilot 
studies limit the generalizability of the findings as well as the statistical analysis.   
There are certain limitations of this review that have to be highlighted at this 
point. It was outside of the control of the author to thoroughly search for the grey 
literature, therefore the review did not provide sufficient measures to control for a 
publication bias increasing the chances of reporting results, which were statistically 
significant. Similarly, the search strategy was limited to articles published in English 
and the studies included in the review mostly relied on an English-speaking white 
male population. These characteristics limit the generalizability of the findings to a 
more diverse population.   
Implications for Research and Practice 
This review highlights the need for longitudinal studies, in order to control for 
a range of confounding variables, in particular, the polydrug use among participants. 
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The evidence from RCTs in the laboratory conditions is lacking ecological validity, 
therefore, the future studies should take into account the wider context of the MDMA 
experience. It is particularly important to think about the set and setting of the drug 
use as defined by Zinberg’s model (Zinberg, 1994) and the relationship between those 
factors. In particular, how they can mediate the effects of MDMA on emotional 
processes.  
Secondly, this review highlights the issue of purity of the drug investigated in 
the studies. Future naturalistic studies should consider controlling for purity and doses 
of the drug consumed by participants. It is also important to separate the findings 
related to chemically pure MDMA often used in clinical trials and laboratory studies, 
from studies addressing the street drug ‘ecstasy’ containing up to several other active 
substances (Cole et al., 2002; Vogels et al., 2009). Future studies should also focus on 
investigating if there are psychological differences in the effects between pure 
MDMA and drugs sold as ‘ecstasy’.  
Thirdly, there is a great need to investigate gender differences in the effects of 
MDMA or ‘ecstasy’. This review revealed significant disproportions in gender ratio. 
The recreational context of the drug use is mostly represented by male participants, 
whereas, the studies addressing the therapeutic use of MDMA mostly relied on female 
participants. It is of a great importance to address the gender imbalance in future 
studies.  
Since the preliminary studies investigating safety and efficacy of MDMA-
assisted psychotherapy brought promising results, future trials are warranted. The 
upcoming studies should use larger sample sizes and address the issue of transparency 
of blinding to participants and therapists, by using an active placebo group. Although, 
one study did use a low dose of MDMA deemed not high enough to be potentially 
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therapeutic as an active placebo, it was found to cause some uncomfortable side 
effects on a small number of participants. Therefore, it would be better to use a 
substance that has somehow similar effects on participants but with minimal side 
effects.  
Although the treatment model of MDMA-assisted therapy is still at its infancy 
and poses significant clinical and ethical dilemmas associated with its legal status and 
our limited understanding of its potential neurotoxic effects, there are certain 
advances it can bring to the find of clinical psychology.  The potential use of MDMA 
in a controlled clinical setting provides an interesting avenue for developing a new 
psychotherapy approach to trauma and PTSD. This is particularly relevant for 
understanding neurological basis for treatment of trauma survivors. The use of 
MDMA alongside more traditional therapy models might alter the way therapy is 
delivered and potentially minimise engagement difficulties and facilitate development 
of the therapeutic alliance, as a catalyst of the therapeutic process (Adamson & 
Metzner, 1988). The preliminary studies are indicative of MDMA shifting an 
emphasis in treatment from cognitive processes to more emotionally loaded and 
experiential processes, where therapists are less active in their roles as MDMA 
experience unfolds (Danforth, Struble, Yazar-Klosinski, & Grob, 2016).  
The traditional CBT model of trauma work assumes that the anxiety response 
and cognitive appraisal can be adapted through re-processing of traumatic memories 
(Ehlers & Clark, 2000). However, this process is often hindered by intolerable levels 
of anxiety and avoidance, which often results in high levels of treatment dropouts 
(Kar, 2011). MDMA-assisted therapy might be perceived by patients as a less 
threatening form of treatment due to its unique effects, which allow the client to feel 
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safe yet at the same time enabling connection with difficult feelings associated with 
trauma, as a result, aiding the processing of traumatic memories (Sessa & Nutt, 2015).  
Conclusions 
In conclusion, there have been a number of advances in the literature 
exploring the effects of MDMA on emotions and pro-social behaviour over the past 
decade. With regards to recreational use, there is robust early evidence that MDMA 
alters emotional process by increasing positive and diminishing negative emotions. 
Due to some contradicting results, it is unclear, however, how MDMA affects the 
ability to recognise emotions in others.  
The studies to date also provided evidence that MDMA affects sociability and 
pro-social behaviours by elevating the value of social interactions and intimacy with 
others. MDMA was found to increase emotional empathy, whereas the relationship 
between cognitive empathy and emotional intelligence, and MDMA remains unclear. 
There is also some preliminary evidence that MDMA might increase self-compassion 
and help reduce self-criticism.  
Regarding the use of MDMA in a therapeutic capacity, the preliminary studies 
provide some compelling evidence that the drug might be successful in treating 
treatment-resistant PTSD. Methodological issues have impacted the potential for 
interpretation and generalizability of findings, and further research addressing both 
recreational and therapeutic use of MDMA is warranted.  
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Abstract 
Zinberg's Interaction Model implies that the content of a drug-induced experience is a 
function of the pharmacological properties of the drug, the set (the user’s 
characteristics e.g. motivation and personality), and the setting (the physical and 
social context). The current research investigated the function of the set and setting 
and their role in shaping the psychological effects of 3,4-
methylenedioxmethamphetamine (MDMA), as well as their role in reducing the risk 
of drug abuse.   
An online survey was distributed among adult MDMA polydrug users (n = 158) and 
MDMA-naïve controls (alcohol, nicotine and cannabis users, n = 138). Participants 
answered questions regarding their pattern of drug use, their motivation for MDMA 
use and the setting (e.g. clubbing, home with friends), as well as the subjective effects 
of MDMA. Participants also completed a range of self-report measures of self-
reflection and insight, emotional intelligence, and personality, as well as a drug 
dependency measure.  
MDMA users displayed higher levels of self-reflection and insight, openness to new 
experience and lower levels of neuroticism and conscientiousness, in comparison to 
non-MDMA users. The significant predictors of self-reflection and insight were 
openness, emotional intelligence, MDMA use, extraversion and neuroticism.  When 
the analysis was rerun only for the MDMA group, the significant predictors of self-
reflection and insight were openness, emotional intelligence and self-insight effects of 
MDMA. High levels of self-reported negative effects of MDMA were predictors of a 
problematic drug use.  
These findings suggest that there might be a relationship between MDMA use and 
higher levels of self-reflection and insight; however, longitudinal studies are required 
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to further investigate the causality of this relationship. The results add to existing 
evidence that MDMA has potential for altering emotional experiences.  
 
Key words: MDMA (Ecstasy), psychological effects, personality, emotional 
intelligence, insight 
  
PSYCHOLOGICAL EFFECTS OF MDMA 
 
 59 
Introduction 
3,4-methylenedioxmethamphetamine (MDMA) is a popular recreational psychoactive 
drug, often referred to as a ‘club drug’, with unique psychological effects on humans 
(Holland, 2001). Population-based studies continue to provide evidence of high rates 
of MDMA use among young people around the world (Barratt, Ferris, & Winstock, 
2014; Morgan, Noronha, Muetzelfeldt, Fielding, & Curran, 2013).  
MDMA is commonly called ‘ecstasy’ (Holland, 2001); however, research 
shows variation in the MDMA content of ecstasy tablets, and the presence of other 
adulterants (Cole, Bailey, Sumnall, Wagstaff, & King, 2002; Doblin et al., 2014; A. 
C. Parrott, 2004). Little is known about the association between the composition of 
ecstasy tablets, and the effects experienced by drug users.  
Brunt, Koeter, Niesink, and van den Brink (2012) reported findings that 
ecstasy tablets with higher MDMA content showed stronger association with 
desirable subjective effects. However, due to difficulty determining the non-MDMA 
additions and adulterants in ecstasy tablets, it has not been possible to confidently 
attribute findings of such studies directly to MDMA.  
Psychological effects of MDMA can enhance emotional bonding with others, 
as well as reducing anxiety and improving social interactions and emotional 
regulation (Johansen & Krebs, 2009). Frye, Wardle, Norman & de Wit (2014) 
reported that taking MDMA reduces social exclusion phenomena. Similarly, MDMA 
enhanced levels of shared empathy and pro-social behaviour in comparison to placebo 
(Hysek, Schmid, et al., 2014). Participants given MDMA were also found to be more 
likely to use words relating to friendship, support and intimacy, and compassion 
(Baggott, Kirkpatrick, Bedi, & de Wit, 2015; Bedi et al., 2014).  
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However, MDMA might also be associated with negative effects such as low 
mood, which is likely to be associated with serotonin depletion, lasting several days 
after consumption (Parrott, 2002). Furthermore, MDMA can be neurotoxic which 
raise concerns that MDMA use may lead to adverse effects on executive functions; in 
particular, verbal memory (eg. Hoshi, Bisla, & Valerie Curran, 2004) and decision-
making (eg. Hanson, Luciana, 2004). On the contrary, other studies report a lack of 
adverse effects on these areas (Back-Madruga et al., 2003;  Gouzoulis-Mayfrank et 
al., 2000).  
Although there has been a recent increase in the number of studies 
investigating the effects of MDMA (Amoroso, 2015; Bedi, Hyman, & de Wit, 2010), 
the literature on factors altering the effects of MDMA remains limited. The current 
research aimed to investigate the function of the set and setting introduced by Zinberg 
(1994), their role in shaping the psychological effects of MDMA, and their function in 
reducing the risk of the drug abuse. The model implies that the content of a drug-
induced experience is a function of the pharmacological properties of the drug, e.g. its 
dose and presence of adulterants; the set, defined as the user’s characteristics e.g. 
one’s motivation and personality, and the setting, defined as the physical and social 
context in which intoxication occurs (Zinberg, 1994). Elements of the set and setting 
concerning MDMA use are described in more depth in the following sections. 
Set  
In context of discussing individual characteristics relevant to MDMA use, the 
set is defined as a range of factors which may contribute to individual differences in 
the effects of MDMA (Zinberg, 1994). Individual qualities such as motivation for 
drug use (Sumnall, Cole, & Jerome, 2006), personality traits and emotional 
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intelligence have been identified as one of the most prominent elements of the set 
(Shewan, Dalgarno, & Reith, 2000; Shewan & Dalgarno, 2005).  
Openness to experience (McCrae & Costa, 2004) was found to be associated 
with novelty seeking behaviour and attentiveness to inner feelings, whereas 
extraversion (McCrae & Costa, 2004) was found to be related to sociability and 
tendency to seek stimulation in the company of others. There is considerable evidence 
that high novelty seekers are at increased risk of abusing drugs in comparison to low 
novelty seekers (Bardo, Donohew, & Harrington, 1996).  
Research on personality characteristics of MDMA users is limited. Only one 
study to date has investigated personality profiles of MDMA users; ter Bogt, Engels 
& Dubas (2006) linked MDMA use in a club setting to higher levels of extraversion 
and lower levels of conscientiousness. Taking into account the previous result, it 
seems plausible that, in comparison to the general population, MDMA users might be 
more likely to present a higher level of extraversion and openness to experience.  
Similarly, MDMA users might be likely to become more attentive to their 
inner feelings in response to deceased levels of anxiety and defensiveness as a result 
of the drug use (Greer & Tolbert, 1986). This in turn might lead to emotional insight, 
as has previously been observed in qualitative accounts of MDMA users (Greer & 
Tolbert, 1986; Liester, Grob, Bravo, & Walsh, 1992). However, not all users report 
emotional insight as a result of MDMA use (Greer & Tolbert, 1998), which suggest 
that this particular effect might be associated with the individual’s set’, for example 
motivation for drug use to gain self-insight, emotional intelligence, and personality. 
Different reasons for MDMA use were associated with alterations in the type and 
degree of subjective effects of MDMA. For example, individuals taking MDMA to 
socialise reported significantly greater pro-social effects (Sumnall et al., 2006). 
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However, no previous studies have examined the relationship between personal 
qualities and motivation for drug use, and psychological effects of MDMA.  
Therefore, this study investigated the role of motivation for drug use in shaping the 
effects of MDMA. Specifically, this study examined whether being motivated to use 
MDMA by the desire to gain self-insight is associated with higher levels of self-
reflection and insight.  
Furthermore, research suggests that higher levels of emotional intelligence are 
significantly associated with users taking ecstasy-related precautions such as 
monitoring drug and fluid intakes, or taking breaks from dancing (Craig, Fisk, 
Montgomery, Murphy, & Wareing, 2010). Higher levels of emotional intelligence 
have also been associated with decreased levels of the adverse effects of MDMA 
(Craig et al., 2010). Therefore, the current study also explored relationships between 
emotional intelligence, motivation for drug use, the psychological effects of MDMA 
and the setting in which intoxication occurs. Taking into account previous evidence in 
the literature, it is likely that higher levels of emotional intelligence will be associated 
with lower levels of adverse effects of MDMA and higher levels of positive effects. 
The following section elaborates further on the concept of setting in terms of the 
social context of the drug experience.  
Setting 
Research investigating the effects of MDMA suggests that the drug can be 
used safely as a therapeutic tool alongside traditional psychotherapy for treatment-
resistant PTSD (Mithoefer et al., 2013; Oehen, Traber, Widmer, & Schnyder, 2013). 
However, it can also become a drug of abuse in other environments such as dance 
clubs (Leung, Ben Abdallah, Copeland, & Cottler, 2010). The above implies the role 
of set and setting in shaping the effects of MDMA. The use of the drug in social 
PSYCHOLOGICAL EFFECTS OF MDMA 
 
 63 
settings is very common and many users claim that they take MDMA predominantly 
to experience its pro-social effects (Sumnall et al., 2006). It has been shown that many 
other drugs, such as alcohol, are experienced as more pleasurable when the 
consumption occurs in a social context (Kirkpatrick & de Wit, 2015). A recent study 
(Kirkpatrick & de Wit, 2015) indicated that the pro-social effects of MDMA can also 
be reinforced by the presence of other people. 
Previous research revealed that some people typically use MDMA outside of a 
club setting in order to gain self-insight and to overcome relationship or emotional 
difficulties (Almeida & Silva, 2003; Boeri, Sterk, & Elifson, 2004; Liester et al., 
1992; Solowij, Hall, & Lee, 1992).  
Risk of MDMA abuse 
Finally, the study also investigated the risk factors of MDMA abuse. A study 
by Shewan et al., (2000) indicated that risk reduction coping strategies such as 
planning, preparation and monitoring of the drug effects, and use of social support 
networks among MDMA users were associated with participants’ awareness of these 
risks, and of the set and setting. This in turn was associated with reduced risk of 
adverse effects of the drug. Furthermore, hedonistic motivation to drug use, e.g. 
taking the drug for fun or pleasure was associated with increased risk of drug abuse 
(Shewan et al., 2000). This study investigated potential predictors of problematic use 
of MDMA, taking into account all elements of the set and setting.  
Aims and Rationale 
Changes observed in emotional processing of social information under the 
influence of MDMA might underlie its possible psychotherapeutic benefits (Metzner 
& Adamson, 2001). Further investigation of such mechanisms could inform treatment 
design of MDMA-assisted psychotherapy. 
PSYCHOLOGICAL EFFECTS OF MDMA 
 
 64 
Therefore, it seems paramount to further investigate possible differences in the 
effects of the drug depending on the set, namely the motivation and personality traits 
and the setting in which people take drugs. Investigating the setting of MDMA use is 
particularly important in order to gain better knowledge of the applicability of 
MDMA as therapeutic agent in psychotherapy.  
Gaining a better understanding of different elements of the set and setting 
influencing MDMA effects might improve effectiveness of MDMA-assisted 
psychotherapy. Furthermore, there might be some scope to use the findings to inform 
a risk-reduction initiative among MDMA users and provide a better understanding of 
the risk factors among health professionals. In particular, the role of personality traits 
as well as emotional intelligence in shaping drug taking behaviours was examined. 
This is the first quantitative study to explore the relationship between personality, 
emotional intelligence, and self-reflection and insight, in the context of MDMA use.  
Research Questions 
This research addressed the below research question and hypotheses: 
1. Which personality traits are associated with MDMA use? It is hypothesized 
that MDMA group will present higher levels of openness to experience and 
extraversion, than the comparison group.   
2. Do elements of the set influence the psychological effects of MDMA (i.e. 
insight, self-reflection)? It is hypothesized that the use of MDMA for self-
reflection will be significantly associated with higher levels of insight and 
self-reflection. 
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3. Does emotional intelligence affect the levels of positive and negative effects 
of MDMA? It is hypothesized that higher levels of Emotional Intelligence will 
be associated with more positive effects and less adverse effects of MDMA. 
4. Does setting of MDMA use (e.g. home environment or dance setting) 
influence the effects of MDMA? 
5. Is there a relationship between the setting of MDMA use (e.g. home 
environment or dance setting) and different motives for MDMA use? 
6. What elements of the set and setting are associated with a reduction of risk of 
drug abuse?  
Methods 
Participants 
The study used a between-group cross-sectional design. All participants were 
English-speaking and aged 18-65. MDMA-users were recruited from drug-related 
forums such as Erowid, Bluelight, and drug-related social groups on Facebook. 
Participants from the comparison group were recruited from non-drug related social 
groups and websites. Participants were not offered any incentive to take part in the 
study. A total of 604 participants took part in the study, of which 293 dropped out 
before completion. Of the remaining 311, 15 cases were excluded from the analysis 
due to a high percentage (45-65%) of their data missing.  
The remaining 296 participants were assigned to one of the two groups based 
on their self-reported history of drug use: the MDMA group (n = 158), or the 
comparison group (MDMA-naïve participants, n = 138). Participants who had used 
MDMA or ecstasy at least once in the past 12 months, and at least three times in their 
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lifetime, were assigned to the MDMA group. Participants who had no previous 
experience of using MDMA or any other drugs apart from alcohol, nicotine, or 
marijuana were allocated to the comparison group.  
The inclusion criteria (described above) were very generic to capture a wide 
variety of drug users. Many studies targeted participants who were abusing the drug, 
therefore arriving at a non-representative sample of MDMA users. Based on Cohen’s 
guidelines (1992), with alpha-level of .05 and the recommended power of .8, the 
sample size of each group was large enough to detect a medium effect size r = .3.  
Materials  
The University of East London drug use questionnaire (UEL drug use 
questionnaire, Parrott, Sisk, & Turner, 2000). The questionnaire collects information 
about details of participants’ own and their immediate family’s psychiatric history as 
well as drug use history. MDMA users are also required to provide further 
information concerning patterns of their drug use: the duration of MDMA use; the last 
time taken.  
The Motives Questionnaire (ter Bogt & Engels, 2005), measures motives for 
MDMA and includes 28 items concerning energy, euphoria, and self-insight 
(Enhancement Motives), sociability/flirtatiousness and sexiness (Social Motives), 
coping (Coping Motive), and conformism (Conformism Motive). All items have the 
form of “I take MDMA because/to/for…’’ and had the format of five-point Likert 
scales (1 ‘definitely not,’ 5 ‘definitely so’). The scale demonstrated good internal 
validity: .66 (ter Bogt & Engels, 2005).  
Perceived Positive and Negative Effects Scales (ter Bogt & Engels, 2005). Positive 
effects of MDMA were measured with a subset of 24 items assessing the energising, 
mood enhancing, and entactogenic effects of MDMA users’ experiences. Examples of 
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items are ‘euphoria, feel absolutely great, open, sensitive’. The scale demonstrated 
good internal validity: .91. Negative effects were measured with a subset of 11 
negative psychological and physical effects. The scale demonstrated good internal 
validity .85 (ter Bogt & Engels, 2005).  
The Self- Reflection and Insight Scale (SRIS; Grant, Franklin, & Langford, 2002). 
SRIS is a questionnaire asking subjects to rate the extent to which they agree or 
disagree with 20 statements on a five-point Likert-type scale. The test consists of 
three subscales: recognition of the need for reflection, the process of engaging in 
reflection and the presence of insight. The scale demonstrated good test-retest 
reliability .77 - .78, and construct validity: .87 - .91 (Grant et al., 2002).  
The NEO Five-Factor Inventory (NEO-FFI, McCrae & Costa, 2004). NEO-FFI 
measures five basic personality factors: neuroticism, agreeableness, 
conscientiousness, extraversion and openness. The instrument uses a five-point Likert 
response format. Two-week retest reliability is uniformly high, ranging from .86 to 
.90 for the five scales (and internal consistency ranges from .68 to .86). 
The Severity of Dependence Scale (SDS; Martin, Copeland, Gates, & Gilmour, 
2006). SDS is a five-item scale measuring the degree of psychological dependence 
experienced by drug users. The statements are specifically related to impaired control, 
preoccupation and anxieties about drug use. The validity of the scale on different 
samples was between .81-.9, test-retest reliability .88 (Gossop et al., 1995).  
 The Trait Emotional Intelligence Questionnaire-Short Form (TEIQ-SF; Cooper 
& Petrides, 2010). TEIQ-SF consists of 30 items measuring global trait emotional 
intelligence (e.g., “I usually find it difficult to regulate my emotions”; “I’m usually 
able to influence the way other people feel”). The scale demonstrated good construct 
validity: between .83-.93, test-retest reliability .76 (Cooper & Petrides, 2010).  
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Procedure 
Ethical approval was received from University Ethics Committee (see 
Appendix 3). Participants were provided with information about the purpose of the 
research before they decided to take part in the study. They were told that they could 
withdraw at any point of completing the survey. It was identified that participants 
could have experienced negative effects, discomfort or distress while participating in 
the survey, in particular when answering questions about the potential negative effects 
of the drug. In order to minimise any discomfort, participants were automatically 
redirected to a website (“Drugs Meter,” n.d.), where they could find reliable 
information on drug harm reduction and how to access support if they recognised 
their drug use being problematic. They were also advised to contact their GP if they 
felt they needed some advice regarding their drug use. Also, the participants were 
encouraged to contact the researcher for any queries, thoughts or feedback with 
regards to the study.  
An online survey containing all the above questionnaires was created and 
distributed among the MDMA users and controls. The data collection was carried out 
between March and September 2015. Participants were asked to answer questions 
regarding their pattern of MDMA and other drug use, set and setting of MDMA use, 
history of psychiatric illnesses, and the positive and negative effects. They also 
completed a range of psychological measures. On average, the participants spent 40 
minutes competing the survey.  
Results 
Data Analysis  
The analysis was conducted using IBM SPSS version 22. Parametric 
assumptions were checked before analysis.  A normal distribution was assessed using 
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the Shapiro-Wilk test, box plots, skewness and kurtosis. Non-parametric tests were 
used for variables which did not meet the criteria for parametric analysis.  
Missing Values Analysis has been applied to analyse the pattern of the 
missing data. In order to account for the data that has been randomly missing, 
multiple imputation procedure has been implemented. Chi2-test and, in cases where 
chi2-test’s assumptions were violated, Fisher’s exact test, were used to compare group 
differences in categorical socio-demographic variables and history of mental health 
illness. Independent samples t-test as well as Mann-Whitney u-test, in cases of not 
normally distributed variables, were used to compare group differences in age and all 
the psychological measures. Pearson’s correlation coefficient was used to assess the 
relationships between different elements of the set and setting. Hierarchical multiple 
regression analysis was carried out to check for predictors of self-reflection and 
insight as well as the risk of drug dependence.  
Cronbach’s alpha was used to assess internal consistency of all scales and 
subscales of the questionnaires (Gliem & Gliem, 2003). As presented in Table 5 in 
Appendix 2, all questionnaires showed good levels of internal consistency.  
Descriptive Statistics 
Socio-demographic variables.  Descriptive statistics concerning all demographic 
variables are presented in Table 1. Mann-Whitney u-test for age, and chi-square test 
for the remaining variables, were used to assess whether the groups differed on any of 
the demographic characteristics. 
There were significant group differences in gender, with females representing 
70% of the comparison group, and only 42% of the MDMA group, c2 (1, N = 296) = 
23.18, p < .001. Similarly, the control group had a higher percentage of participants in 
a relationship (70%, MDMA group = 57%), c2 (1, N = 295) = 5.32, p = .021, as well 
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as some form of employment, c2 (4, N = 296) = 18.89, p = .001. However, the MDMA 
group had greater numbers of students (22%, comparison group = 12%), which was 
reflected in the differences in the levels of education, where the same percentage of 
participants in the MDMA group had some years of college but no degree, c2 (5, N = 
296) = 20.15, p = .001. 
There were no significant group differences in sexual orientation, c2 (2, N = 
295) = 4.96, p = .084, and age, p = .26 (SPSS version 22 does not report test statistics 
for Mann-Whitney u-test, therefore only p value is reported).  However, histograms 
presented in Appendix 2, illustrated some important group differences. The most 
numerous subgroup in the MDMA group were young people in their early twenties, 
most likely accounting for the student population, whereas the comparison group was 
represented by young adults in their late twenties. These might account for the 
differences in education levels, employment status and the relationship status.  
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Table 1  
Group comparison: demographic variables 
 MDMA Group 
n      M      (SD) 
Comparison group 
n      M     (SD) 
 
Total 
n      M     (SD) 
Age (years) 158   29.80 (9.816) 138 29.66 (7.695) 296 29.73 (8.878) 
  
MDMA Group 
n     % 
 
Comparison group 
n      % 
 
Total 
n      % 
Gender    
Male 91   57.6% 41   29.7% 132   44.6% 
Female 67   42.4% 97   70.3% 164   55.4% 
Total 158   100% 138   100% 296   100% 
Relationship status 
Single 
 
67   42.7% 
 
41   29.7% 
 
108   36.6% 
In a relationship 90   57.3% 97   70.3% 187   63.4% 
Total 157   100% 138   100% 295   100% 
Sexual orientation 
Heterosexual 
 
123   77.8% 
 
120   87.6% 
 
243   82.4% 
Gay or lesbian 8    5.1% 3   2.2% 11   3.7% 
Bisexual 27   17.1% 14   10.2% 41   13.9% 
Total  158   100% 137   100% 295   100% 
Employment  
Employed for wages 
Self-employed 
Looking for work 
Not looking for work 
A student 
Total 
 
69   43.7% 
 
93   67.4% 
 
162   54.7% 
29   18.4% 11   8.0% 40   13.5% 
14   8.9% 8   5.8% 22   7.4% 
10   6.3% 9   6.5% 19   6.4% 
36   22.8% 17   12.3% 53   17.9% 
158   100% 138   100% 296   100% 
Education 
High school or less 
 
21   13.3% 
 
7   5.1% 
 
28   9.5% 
Some years of 
college, no degree 
36   22.8% 19   13.8% 55   18.6% 
Bachelor’s degree 59   56.7% 45   32.6% 104   35.1% 
Master’s degree 28   17.7% 50   36.2% 78   26.4% 
Professional degree 8   5.1% 7   5.1% 15   5.1% 
Doctorate degree 6   3.8% 10   7.2% 16   5.4% 
Total 158   100% 138   100% 296   100% 
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Mental Health and Substance Use.  Chi2-test and, in cases where chi2-test 
assumptions were violated, Fisher’s exact test, were used to assess group differences 
in history of mental health illness. Table 2 shows that there were no significant group 
differences in the prevalence of mental health illness, such as anxiety disorders, 
depression and obsessive-compulsive disorder (OCD), schizophrenia and addiction. 
Only 2% of the MDMA group received treatment for addiction to substances, in 
contrast with none in the comparison group. Similarly, the numbers of alcohol and 
tobacco users did not differ between the groups. However, the MDMA group had 
significantly higher numbers of cannabis users than the comparison group, 59% and 
32%, respectively, c2 (1, N = 290) = 20.57, p < .001.  
In terms of the MDMA use, less than 4% of participants from the MDMA 
group displayed some levels of MDMA dependence. The vast majority were 
classified as non-problematic drug users based on the Severity of Dependence Scale 
cut-off score of five and above being indicative of a problematic drug use (Topp & 
Mattick, 1997). See Table 8 in Appendix 2 for more details.  
Table 3 presents the drug use profile in the MDMA group. The majority of the 
sample were light (up to 10 times in a life time, 36%) to moderate users (up to 40 
times in a life time, 28%). Other frequently used drugs were cannabis, ecstasy, 
magic mushrooms, LSD and cocaine. Apart from cannabis, in which the vast 
majority of those who used it reported heavy use, the other commonly used drugs 
were categorised as having light to moderate use. 
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Table 2  
Mental health history, alcohol, cannabis and tobacco: group differences 
 MDMA Group 
n     % 
 
Comparison 
group 
n      % 
 
Total 
n      % 
Chi
2 
test/ 
Fisher’s  
    Exact Test* 
df sig.  
MDMA 
Dependence 
      
Yes   6    3.8%  -   6    3.8% - - - 
No 144  91.1%           - 144  91.1%    
Treatment for: 
Addiction  
Yes 
 
 
4   2.7% 
 
 
0   0% 
 
 
4   1.4% 
 
 
-* 
 
 
- 
 
 
0.124 
No 146   97.3% 136   100% 282   98.6%   
Anxiety  
Yes 
 
  21   13.7% 
 
22   16.2% 
 
43   14.9% 
 
0.342 
 
1 
 
0.621 
No 132   86.3% 114   83.8%  246   85.1%    
Depression       
Yes 38   24.7% 34   24.8% 72   24.7% 0.001 1 1.000 
No 116   75.3% 103   35.4% 219   75.3%    
OCD       
Yes 4   2.7% 1   0.7% 5   1.7% -* - .374 
No 146   97.3% 135   99.3% 281   98.3%    
Schizophrenia       
Yes  3     2% 0   0% 3   1% -* - .249 
No    147   98% 136   100% 283   99%    
Drink Alcohol       
Yes 129   82.7% 108   78.3%    237   80.6% 0.920   1 0.376 
No 27   17.3% 30   21.7% 57   19.4%    
Smoke Cannabis       
Yes 90   59.2% 45   32.6 135   46.6% 20.572 1 0.000 
No 62   40.8% 93   67.4 155   53.4%    
Smoke Tobacco       
Yes 
No 
64   40.8% 42   30.4% 106   35.9% 3.404 1 0.069 
93   59.2% 96   69.6% 189   64.1%    
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Table 3  
Drug use profile 
 
 
Drug 
None 
 
Light 
1-10 x 
Moderate 
11-40x 
Heavy 
41-100x 
Very heavy 
>100x 
n % n % n % n % n % 
 
MDMA 
 
11 
 
7% 
 
57 
 
36.1% 
 
44 
 
27.9% 
 
35 
 
22.1% 
 
11 
 
7% 
Ecstasy 36 22.8% 44 27.8% 42 26.5% 21 13.3% 15 9.5% 
Amphetamine 65 41.1% 44 27.8% 28 17.7% 8 5.1% 13 8.2% 
Mephedrone  108 68.4% 36 22.8% 10 6.3% 2 1.3% 2 1.3% 
Cocaine 47 29.7% 57 36.1% 32 20.3% 12 7.6% 10 6.3% 
Crack 142 89.9% 15 9.5% 1 0.6% - - - - 
LSD 44 27.8% 62 39.5% 32 20.3% 10 6.3% 10 6.3% 
 
DMT 
 
93 
 
58.9% 
 
49 
 
31% 
 
10 
 
6.3% 
 
6 
 
3.8% 
 
- 
 
- 
Cannabis 12 7.6% 4 2.5% 19 12% 24 15.2% 99 62.7% 
Barbiturates 148 93.7% 5 3.2% 5 3.2% - - - - 
Benzodiazepines 72 45.6% 45 28.5% 22 13.9% 9 5.7% 10 6.3% 
Opiates 125 79.1% 20 12.7% 7 4.4% 2 1.3% 4 2.5% 
Magic 
Mushrooms 
35 22.2% 74 46.8% 38 24.1% 6 3.8% 5 3.2% 
Steroids 156 98.7% 2 1.3% - - - - - - 
 
Solvents 
 
142 
 
89.9% 
 
8 
 
5.1% 
 
6 
 
3.8% 
 
1 
 
0.6% 
 
1 
 
0.6% 
Poppers 95 60.1% 38 24.1% 16 10.1% 6 3.8% 3 1.9% 
Ketamine 82 51.9% 48 30.4% 19 12% 4 2.5% 5 3.2% 
Prozac 144 91.1% 4 2.5% 3 1.9% 2 1.3% 5 3.2% 
Viagra 136 86.1% 16 10.1% 3 1.9% 1 0.6% 2 1.3% 
GHB 130 82.3% 22 13.9% 4 2.5% 2 1.3% - - 
 
Legal Highs: 
Synthetic 
cannabis 
 
 
119 
 
 
75.3% 
 
 
31 
 
 
19.6% 
 
 
6 
 
 
3.8% 
 
 
- 
 
 
- 
 
 
2 
 
 
1.3% 
pills 136 86.1% 16 10.1% 3 1.9% 1 0.6% 2 1.3% 
others 134 84.8% 17 10.8% 4 2.5% 2 1.3% 1 0.6% 
 
PSYCHOLOGICAL EFFECTS OF MDMA 
 
 75 
 
Inferential statistics 
Set: Personality Traits.  It has been hypothesised that MDMA users will be 
presenting with higher levels of openness to experience and extraversion than the 
comparison group. This hypothesis was tested using independent sample t-test (see 
Table 4). Due to running a series of independent t-tests, the Bonferroni correction was 
applied and α level was adjusted to .0045 (Field, 2009).  
  The MDMA group has shown higher levels of openness to experience than the 
control group, t (26991003) = 6.782, p < .001, d = .79; but did not differ with regards 
to the levels of extraversion. Additionally, independent t-test revealed that the 
MDMA group presented lower levels of neuroticism, t (51444913) = -2.99, p = .003, 
d = -.347; and conscientiousness t (34897668) = -3.09, p = .002, d = -.36, in 
comparison to the controls. There were no group differences in agreeableness.  
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Table 4  
Psychological measures: groups comparison. 
  N Mean SD t-test df sig.  Cohen’s d 
SRIS_FULL_SCALE MDMA  158 80.07 9.171 4.782 35751749 .000 .555 
Control  138 74.87 9.568 
Engaging in Self Reflection MDMA  158 25.55 3.846 4.196 2626678 .000 .486 
Control  138 23.52 4.482 
Need for Self Reflection MDMA  158 25.85 3.703 4.875 17851609 .000 .606 
Control  138 23.61 4.226 
Insight MDMA  158 28.67 4.886 1.663 33919052 .096  
Control  138 27.75 4.568 
TEIQ Emotional Intelligence MDMA  158 151.87 25.088 1.808 19715479
73 
.071  
Control  138 146.57 25.398 
NEO FFI Full Scale MDMA  158 145.35 13.024 .043 18499771 .965  
Control  138 145.28 14.346 
NEO FFI Neuroticism MDMA  158 21.76 10.407 -2.996 51444913 .003 -.347 
Control  138 25.34 10.211 
NEO FFI Extraversion MDMA  158 28.45 6.590 1.925 26721827.
965 
.054  
Control  138 26.79 8.058 
NEO FFI Openness MDMA  158 36.35 5.481 6.782 26991003 .000 .786 
Control  138 31.77 6.156 
NEO FFI Agreeableness MDMA  158 31.16 5.639 .231 370958 .817  
Control  138 31.01 6.203 
NEO FFI Conscientiousness MDMA  158 27.63 7.476 -3.087 34897668 .002 -.357 
Control  138 30.37 7.828 
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Self-reflection and insight.  An independent sample t-test was used to check for 
group differences in self-reflection and insight (full scale). As presented in Table 4, 
the MDMA group showed higher levels of the overall self-reflection and insight, than 
the comparison group, t (35751749) = 4.78, p < .000. However, when the individual 
subscales were analysed, engagement in self-reflection and need for self-reflection 
remained significant but the groups did not differ on the insight subscale.  
It has been hypothesised that the use of MDMA for self-reflection will be 
significantly associated with higher levels of insight and self-reflection among 
MDMA users. This hypothesis was tested using Pearson’s correlation coefficient. 
There were significant positive correlations between self-insight motive for MDMA 
use and self-reflection and insight scale, r (156) = .37, p < .05. There was also a 
significant negative correlation between conformism motive and self reflection and 
insight scale, r (156) = .27, p < .001, and insight subscale, r (156) = .31, p < .001 (see 
Table 5 for more details).  
The results suggest that MDMA users who declared using MDMA for gaining self-
insight generally displayed higher levels of self-reflection and insight. On the 
contrary, participants who used MDMA due to conformity (i.e. peer pressure), 
presented with lower levels of self-reflection and insight.  
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Table 5  
Pearson’s correlation coefficients: motives for MDMA use and self-reflection and 
insight 
  
Euph. 
 
Self -
insight 
 
Soc. 
 
Sex 
 
Coping 
 
Conform 
 
SRIS 
Eng. in 
S.R. 
Need 
For S.R. 
Insight 
Energy 
 
.453** -.164* .141 .094 .228* .229* -.070 .026 -.017 -.169* 
Euphoria 
 
 .077 .203* .116 .196* .083 -.042 -.025 -.092 .009 
Self-insight 
 
  .262* .175* .061 -.241*   .365* .258* .301* .245* 
Sociability 
 
   .677** .263** .049 .077 .129 .117 -.045 
Sexiness 
 
    .196* .032 .107 .112 .064 .062 
Coping 
 
     .270** -.115 .033 .004 -.240* 
Conformism 
 
      -.269** -.119 -.120 -.314** 
SRIS 
 
       .846** .823** .561** 
Eng. In S.R.         .844** .096 
Need for 
S.R. 
         .055 
 
**. Correlation is significant at the 0.01 level (2-tailed) 
*. Correlation is significant at the 0.05 level (2-tailed) 
 
Emotional intelligence.  It was hypothesised that higher levels of emotional 
intelligence will be associated with more positive effects and less adverse effects of 
MDMA. Pearson’s correlation coefficient was used to test this hypothesis. The higher 
the levels of emotional intelligence, the higher the levels of self-insight, r (157) = .17, 
p < .05, and sexiness effects of MDMA use, r (157) = .20, p < .05 (Table 6). The 
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strength of the relationship was low. There was no significant correlation between the 
negative effects of MDMA and emotional intelligence.  
Table 6  
Pearson’s correlation coefficients: effects of MDMA and emotional intelligence 
 EI  SDS  Neg. Mood  En. Danc. 
Self-
ins. Comm. Sex 
EI          
SDS -.265**         
Negative -.127 .458**        
Mood .090 -.015 .006       
Energy .055 .085 .083 .534**      
Dancing .072 .023 .112 .326** .554**     
 Self-Insight .165* -.142 -.016 .264** .246** .050    
Communication .059 -.088 .030 .471** .463** .283** .505**   
Sexiness .200* -.133 .067 .374** .358** .343** .246* .327**  
Openness .099 .028 .025 .497** .458** .337** .513** .571** .351** 
 
**. Correlation is significant at the 0.01 level (2-tailed) 
*. Correlation is significant at the 0.05 level (2-tailed) 
 
Setting and effects of MDMA.  For the purpose of this analysis, the four categories 
of the setting of the MDMA use were collapsed into two categories: home setting 
(including ‘home with friends or partner’ and home alone), and dance setting 
(including club setting and music festival setting).  
An explorative analysis has been carried out to check whether the setting of 
MDMA use can influence the effects of MDMA. Pearson’s correlation coefficient 
was used to detect relationships between different variables of set and setting. There 
have been significant positive correlations between dance setting and energy and 
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euphoria effect, r (155) = .23, p = .003 as well as dancing effect, r (155) = .39, p < 
.001. Suggesting that those participants who used MDMA in a dance setting were 
experiencing stronger energy and euphoria effects of MDMA.  
Home setting was positively correlated with emotional intelligence, r (155) = 
.17, p = .030, and conscientiousness, r (155) = .23, p = .005, and negatively correlated 
with dancing effect, r (155) = -.36, p < .001. Participants who declared using MDMA 
in a home setting reported weaker dancing effects, and presented with higher levels of 
emotional intelligence and conscientiousness.   
Setting and motives for MDMA use.  Pearson’s correlation coefficient has 
been used to check whether there was a relationship between the setting of MDMA 
use and the motives. There were significant positive correlations between dance 
setting and energy motive, r (156) = .37, p < .001, and euphoria motive, r (156) = .24, 
p = .002; and a significant negative correlation with self-insight motive, r (155) = -
.16, p = .045. Home setting was significantly and positively associated with self-
insight motive, r (156) = .21, p = .010, and negatively associated with energy motive, 
r (156) = -.33, p < .001. The strengths of the relationships were low to moderate. The 
results suggest that among those whose motivation to use MDMA was to experience 
dancing and energy and euphoria were more likely to use MDMA in a dance setting. 
Conversely, participants whose motivation was to experience self-insight were more 
likely to use MDMA in a home setting.  
Risk of Drug Abuse.  An explorative analysis was carried out to investigate which 
elements of the set and setting may be associated with risk of drug abuse. Firstly, 
Pearson’s correlation coefficient was used. There were significant positive 
relationships between MDMA severity of dependence scale (SDS) and negative 
effects of MDMA, r (154) = .46, p < .001, conformism motive, r (154) = .16, p = 
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.048, and neuroticism, r (156) = .29, p < .001. There were negative relationships 
between SDS and emotional intelligence, r (155) = -.27, p = .001, and 
conscientiousness, r (156) = -.25, p = .002. All the significant correlations were of 
moderate effect size or below.  
Secondly, a hierarchical multiple regression analysis was carried out to find 
out the predictors of SDS. The hierarchical multiple regression was chosen to test the 
effects of certain predictors (Tabachnick & Fidell, 2001), specifically negative effects 
of MDMA. 
The sample size of 158 was large enough for seven independent variables to 
be included in the analysis (Tabachnick & Fidell, 2001). The assumptions of linearity 
and homoscedasticity were checked using residual and scatter plots. The assumption 
of singularity was met and Pearson’s correlations coefficients revealed the lack of 
perfect multicollinearity. The assumptions of independent errors were tested with the 
Durbin-Watson test.  
The variables were entered into the model in three steps. The first step 
included: emotional intelligence, conscientiousness, neuroticism and conformism 
motive. In the second step, negative effects of MDMA was added to the existing 
model. In the third step, age and gender were added to the model. Table 7 presents the 
regression statistics. The model in step 1 explained almost 12% of the variance in 
SDS; R2 = .115, adjusted R2 = .088, F (4, 131) = 4.24, p = .003. Adding negative 
effects of MDMA to the model in step two explained additional 19% of the SDS 
variance and this change in R2 was significant F (1, 130) = 34.50, p < .001. In step 
three, age and gender were added but the model did not improve the ability to predict 
the SDS, R2 change = .003, F (2, 128) = .29, p = .744.  Negative effects of MDMA 
was the only significant predictor of severity of dependence from MDMA. 
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Table 7  
Hierarchical regression: severity of dependence and self-reflection and insight 
 
Severity of Dependence Scale  
(SDS) 
 
Self-Reflection and Insight  
 (Both groups) 
 
Self-Reflection and Insight  
 (MDMA group) 
 B SE B β Sig.  Β SE B β Sig. B SE B β Sig. 
Step 1     Step 1         
Emotional 
intelligence 
-.001 .008 -.019 .892 Openness .630 6.435 .412 .000 .491 .122 .301 .000 
Conscientiou
sness 
-.026 .019 -.132 .162 
Emotional 
Intelligence 
.187 .081 .489 .000 .211 .047 .583 .000 
Neuroticism .029 .020 .198 .149 Agreeableness .005 .095 .003 .959 - - - - 
Conformism 
Motive 
.075 .054 .118 .168 Neuroticism .146 .076 .157 .056 .200 .099 .229 .046 
Step 2     Extraversion -.170 .090 -.132 .060 -.013 .130 -.010 .919 
Emotional 
intelligence 
-.008 .007 -.137 .282 Step 2         
Conscientiou
sness 
-.024 .017 -.121 .152 Openness .539 .087 .352 .000 .393 .122 .241 .002 
Neuroticism .003 .018 .024 .848 
Emotional 
Intelligence 
.198 .035 .518 .000 .189 .046 .521 .000 
Conformism 
Motive 
.031 .049 .048 .528 Agreeableness .040 .095 .025 .675 - - - - 
Negative 
effects 
4.151 .707 .450 .000 Neuroticism .179 .076 .193 .020 .162 .097 .185 .097 
Step 3     Extraversion -.208 .090 -.160 .022 -.012 .126 -.009 -.924 
Emotional 
intelligence 
-.009 .008 -.155 .239 
MDMA 
use/self-
insight 
effects* 
2.808 1.072 .147 .009 2.756* .858* .236* .002* 
Conscientiou
sness 
-.025 .017 -.126 .143 Step 3         
Neuroticism .001 .019 .005 .967 Openness .534 .088 .349 .000 .393 .123 .240 .001 
Conformism 
Motive 
.030 .049 .048 .537 
Emotional 
Intelligence 
.199 .036 .519 .000 .187 .047 517 .000 
Negative 
effects 
4.213 .729 .457 .000 Agreeableness .050 .096 .031 .606 - - - - 
Age .007 .012 .044 .573 Neuroticism .151 .080 .164 .058 .143 .103 .163 .171 
Gender .122 .227 .042 .591 Extraversion -.226 .091 -.175 .013 -.024 .128 -.018 .849 
     
MDMA 
use/self-
insight 
effects* 
2.933 1.090 .154 .008 2.789 .868 .238 .002* 
     Age -.084 .056 -.080 .131 -.031 .066 -.034 .635 
     Gender .565 1.027 .030 .583 .521 1.277 .030 .684 
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Additional Analysis 
Predictors of self-reflection and insight.  The results revealed higher levels 
of the overall self-reflection and insight among the MDMA group, in contrast with the 
comparison group. Therefore, further analysis was carried out to investigate whether 
the use of MDMA, as well as emotional intelligence and personality traits, were 
associated with higher levels of self-reflection and insight.  
Firstly, Pearson’s correlation coefficient was used to determine the strengths 
of the relationships between the variables. Secondly, a hierarchical multiple 
regression analysis was carried out to identify the predictors of SRIS.  
Analysis identified significant positive relationships between SRIS and 
openness, r (156) = .49, p < .001, emotional intelligence, r = .38, p < .001, MDMA 
use, r (156) = .27, p < .001, and agreeableness, r (156) = .22, p < .001, and 
extraversion r (156) = .12, p = .045; and a negative relationship between SRIS and 
neuroticism, r (156) =  -.21, p < .001.  
A hierarchical multiple regression was chosen in order to control for the 
effects of certain predictors (Tabachnick & Fidell, 2001), specifically MDMA use. 
Prior to conducting the analysis, all relevant assumptions were tested as discussed in 
the previous section (Field, 2009).  
The variables were entered into the model in three steps. The first step 
included: openness, emotional intelligence, agreeableness, neuroticism and 
extraversion. In the second step, MDMA use was added to the existing model. In the 
third step, age and gender were added to the model. Table 7 presents the regression 
statistics.  
The analysis revealed that the model in step 1 explained 33.5% of the variance 
in SRIS; R2 = .335, adjusted R2 = .322, F (5, 256) = 25.75, p < .001. Adding MDMA 
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use to the model in step two explained an additional 2% of the SRIS variance and this 
change in R2 was significant F (1, 255) = 6.87, p = .009. When all eight variables 
were added to the model in step three, age and gender were not significant predictors 
of SRIS and the model in step three did not improve the ability to predict the SRIS, R2 
change = .007, F (2, 253) = 1.34, p = .265. The significant predictors of SRIS were 
openness, emotional intelligence, MDMA use, extraversion and neuroticism. 
Together all five predictors accounted for 35% of the variance in SRIS; R2 = .35, 
adjusted R2 = .34, F (6, 255) = 23.09, p < .001.  
Predictors of self-reflection and insight among MDMA users.  A further 
hierarchical regression analysis has been carried out to find out which elements of the 
set and setting were predictors of self-reflection and insight among MDMA users 
only.  
The variables were entered into the model in three steps. The first step 
included: openness, emotional intelligence, neuroticism and extraversion. In the 
second step, self-insight effects was added to the existing model. In the third step, age 
and gender were added to the model. See table 7 for the regression statistics.  
The analysis revealed that the model in step 1 explained almost 32% of the 
variance in SRIS; R2 = .32, adjusted R2 = .30, F (4, 133) = 15.38, p < .001. Adding 
self-insight effects to the model in step two explained an additional 5% of the SRIS 
variance and this change in R2 was significant F (1, 132) = 10.31, p = .002. Similarly 
to the previous analysis, age and gender were not significant predictors of SRIS and 
the model in step three did not improve the ability to predict the SRIS, R2 change = 
.002, F (2, 130) = .202, p = .817. The significant predictors of SRIS among MDMA 
users were openness, emotional intelligence and self-insight effects of MDMA. 
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Together, all predictors accounted for 36.6% of the variance in SRIS; R2 = .37, 
adjusted R2 = .33, F (5, 132) = 15.38, p < .001.  
Discussion 
Set 
The aim of the study was to explore the role of the set and setting in shaping 
the psychological effects of MDMA, as well as their function in reducing the risk of 
drug abuse. MDMA users presented higher levels of openness to experience and 
lower levels of neuroticism, and conscientiousness, in comparison to the controls. 
However, there were no group differences in extraversion and agreeableness.  These 
results were partially in line with a study by ter Bogt et al. (2006), where MDMA 
users reported lower levels of conscientiousness but higher levels of extraversion. 
However, this study was completed on a specific sample of MDMA users who were 
visitors of a rave party, which may be at least partially responsible for the differences 
reported by the studies.  
MDMA users reported higher levels of engagement in self-reflection and need 
for self-reflection but the groups did not differ on the levels of insight. Furthermore, 
the results indicated participants who reported the use of MDMA to obtain self-
reflection and insight displayed greater ability to self-reflect and insightfulness. 
However, participants who stated the use of MDMA due to conformity (i.e. peer 
pressure) reported lower levels of self-reflection and insight. 
The study did not support the hypothesis that higher levels of emotional 
intelligence might be associated with lower levels of the negative effects of MDMA.  
However, the results indicated that participants with higher levels of emotional 
intelligence are more likely to experience self-insight and sexiness effects of MDMA.  
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The result of lower levels of neuroticism among MDMA users was 
unexpected as there were no previous results that would suggest those differences. 
Neuroticism reflects distress proneness and tendencies toward the experience of 
negative affects. It has been documented that women score higher on the traits of 
neuroticism and agreeableness in comparison to men (Costa Jr., Terracciano, & 
McCrae, 2001). It is possible that the differences reported in this study might be due 
to gender differences between the groups, with the majority of the comparison group 
being women.  
Setting 
In terms of the setting of MDMA use, some differences were observed in 
MDMA effects and personality qualities, depending on the environment in which 
participants used the drug. Dance settings (i.e. clubs or music festivals) were 
associated with higher levels of energy and euphoria, as well as reported effects of 
MDMA on participant’s dance subscale score on the Perceived Positive Effects Scale 
(ter Bogt & Engels, 2005). Taking MDMA in a home setting was associated with 
lower levels of the dancing effects of MDMA.  
There was also a weak but significant positive correlation between home 
environment and emotional intelligence and conscientiousness.  This suggests that the 
dance setting might be reinforcing certain effects of MDMA, in this case, the effects 
associated with dancing, energy and euphoria. Whereas people with certain personal 
qualities such as higher levels of emotional intelligence and conscientiousness might 
be preferring more a intimate setting for MDMA use, such as a home environment. 
These findings are supported by a previous study by Sumnall, Cole, & Jerome, 
(2006), which also reported that subjective MDMA experience might be influenced 
by the elements of the setting. 
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Self-Reflection and Insight 
Higher levels of self-reflection and insight were associated with higher levels 
of openness, emotional intelligence and MDMA use, agreeableness and extraversion, 
as well as with lower levels of neuroticism. Among those variables, the significant 
predictors of SRIS were openness, emotional intelligence, MDMA use, extraversion 
and neuroticism.  When the analysis was rerun only for the MDMA group, the 
significant predictors of SRIS were openness, emotional intelligence and self-insight 
effects of MDMA. These findings suggest that there is a relationship between MDMA 
use and higher levels of self-reflection and insight. It is likely that MDMA may 
increase self-reflection and insightfulness, however, due to the cross-sectional nature 
of this study it is impossible to imply a direction of this relationship. The results are in 
line with several qualitative studies which suggested that MDMA use led to increased 
self-insight (e.g. Adamson & Metzner, 1988; Greer & Tolbert, 1986).  At this point, it 
is important to acknowledge the role of other individual factors, in particular, 
personality traits and emotional intelligence, which might facilitate the process of 
psychological insight into one’s emotional state.  
Problematic Use  
Regarding the factors associated with the risk of developing a problematic use 
of MDMA, in this study, higher levels of negative effects of MDMA and neuroticism, 
as well as the use of MDMA due to conformity, were associated with increased levels 
of drug dependence. These results contradict findings from a previous study by Scott, 
Hides, Allen, & Lubman (2013) where coping motives, but not conformity motives, 
were associated with heavier ecstasy use.  
Higher levels of emotional intelligence and conscientiousness were associated 
with lower levels of drug abuse. Among all those variables, only negative effects of 
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MDMA were identified as a significant predictor of the drug dependence syndrome. 
This might suggest that higher levels of reported negative effects of MDMA could be 
a significant indicator of problematic drug use, which may lead to a development of a 
drug dependence syndrome.  
MDMA users did not exhibit increased levels of addiction than the 
comparison group. In fact, less than 3% of the MDMA group received treatment for 
addiction to some form of psychoactive substance. Similarly, the numbers of alcohol 
and tobacco users did not differ between the groups. However, the MDMA group had 
significantly greater numbers of cannabis users than the comparison group. Cannabis 
was also the most frequently used drug among MDMA users.  
The vast majority of the MDMA users were classified as non-problematic 
MDMA users and less than 4% displayed some symptoms of MDMA dependence. 
The majority of the sample were light-to-moderate MDMA users. These findings 
indicated that the self-reported use of MDMA among this group of users put them in a 
relatively low risk category with regards to developing a dependence syndrome 
(Degenhardt, Bruno, & Topp, 2010). As identified in previous studies, the majority of 
MDMA users appeared to decrease or stop using MDMA as part of a natural 
trajectory (Smirnov et al., 2013; Verheyden, Henry, & Curran, 2003). However, these 
results have to be interpreted cautiously since the study included only self-report 
measures of drug dependency.   
Mental Health 
This study revealed the lack of differences between the MDMA users and 
non-MDMA users in the self-reported prevalence of mental health illness, such as 
anxiety disorders, depression, obsessive-compulsive disorder, and schizophrenia. 
Using standardised measures to assess current mental health among participants was 
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outside the remit of this study. However, there are a number of studies indicating 
increased levels of mental health problems among users, in particular among heavier 
MDMA polydrug users (e.g. Milani, 2011; Singer, Linare, Ntiri, Henry, & Minnes, 
2004; Soar, Turner, & Parrott, 2006; Turner et al., 2014). It is conceivable that the 
lack of observed group differences in the prevalence of mental health could be due to 
heterogeneity among MDMA users on wider factors associated with mental health. 
As pointed out by Soar et al. (2006) it is likely that socio-economic variables, as well 
as pre-existing mental health problems, are factors which need to be taken into 
account when interpreting the results. Since almost all MDMA users are polydrug 
users, it is not possible to isolate the effects of MDMA on mental health. Several 
studies indicated that mental health difficulties found in MDMA polydrug users were 
associated with other drug use such as alcohol, marijuana, opioids, and inhalants (e.g. 
Daumann et al., 2004; Falck, Wang, Carlson, & Siegal, 2006; Medina & Shear, 2007). 
Methodological Considerations 
There are a number of limitations to the current study. Firstly, the cross-
sectional design does not allow determination of causality, and limits possible 
conclusions about the direction of the relationships between analysed variables 
(Tabachnick & Fidell, 2001).  
The comparison groups were significantly disproportional in gender, 
relationship status and education. While the sampling method did not allow for these 
to be controlled for in the design of the study, statistically controlling within the 
analysis enabled some degree of confidence that these variables did not significantly 
account for the results. However, lack of standardised measures of mental health 
problems means it was not possible to assess group differences in experiences of 
mental health. These variables therefore could potentially have confounded the 
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results, meaning conclusions of this study have to be interpreted cautiously. Issues 
with the ecological validity of self-report measures of substance use, in absence of 
validation through biological analysis, need to be taken into account when 
interpreting the findings.  
As discussed by many other studies involving polydrug users, work in this 
area is affected by methodological constraints. Due to the illegal status of MDMA and 
the lack of regulations of the content and the purity of the substances sold on the 
streets for recreational use, it is difficult to assess whether the participants actually 
used MDMA or some other chemically related substances available on the market. 
Therefore, it has not been possible, either in previous cross-sectional research or the 
current study, to confidently relate the findings from a sample of polydrug users to 
one particular drug (Gouzoulis-Mayfrank & Daumann, 2006). It is also difficult to 
assess the dose and collect an overall drug use history when relying on self-report 
measures as the only source of data.  
Despite the limitations described above, the study also posses some strengths.  
Firstly, this study used a large sample size and managed to recruit a diverse 
population of MDMA users.  Secondly, the study was the first one to address the role 
of personal qualities and motivation in shaping the effects of MDMA, allowing a 
more comprehensive account of the effects of MDMA to emerge.  
Clinical Implications 
The unique psychological effects of MDMA reported by this study might have 
certain clinical implications for treatment of trauma survivors. Although there are 
successful models of treatment for PTSD such as cognitive-behavioural therapy 
(CBT) and eye-movement desensitization and reprocessing (EMDR; Cukor, 
Spitalnick, Difede, Rizzo, & Rothbaum, 2009; Kar, 2011), a review of the treatment 
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literature indicated that these therapies have relatively large dropout and nonresponse 
rates (Schottenbauer, Glass, Arnkoff, Tendick, & Gray, 2008). Due to high prevalence 
rates of PTSD (Dorrington et al., 2014), there is a need for a more successful and 
acceptable treatment for this condition. Preliminary results of the MDMA-assisted 
therapy for PTSD provide some tentative evidence that MDMA might be a safe and 
acceptable treatment for PTSD, and provided rationale for further randomised 
controlled trials to test its efficacy (e.g. Chabrol, 2013; Oehen et al., 2013).  
This study supported the hypothesis that the effects of MDMA differ with 
regards to set and setting of use providing some overarching explanations to both 
recreational and therapeutic uses. The results might suggest that the therapeutic 
effects of MDMA reported in the literature (Amoroso, 2015) might be associated with 
certain elements of the setting such as the presence of a couple of therapists in the 
room as well as client’s attitude to treatment and personality. These elements should 
be taken into consideration in clinical trials of MDMA-assisted psychotherapy, which 
have recently gained momentum (Mithoefer et al., 2013; Mithoefer, Wagner, 
Mithoefer, Jerome, & Doblin, 2011; Oehen et al., 2013). The finding that openness to 
experience, extraversion as well as emotional intelligence, and the individual’s 
motivation to experience insight might be associated with increased levels of self-
reflection and insight, might in turn be useful in developing effective therapeutic 
interventions employing MDMA.  
Regarding the problematic use of MDMA, this study identified that high 
levels of negative effects of MDMA might be a strong predictor of a development of a 
dependence syndrome. This information might be used by substance misuse 
programmes aimed at increasing awareness of drug use among young people, as well 
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as for drug and mental health workers supporting people who might be at risk of 
developing a problematic pattern of drug use.  
Future Research 
In order to address the methodological issues identified above, there is a need 
for longitudinal and prospective research designs. This could lead to a better 
understanding of the relationships between MDMA use and their psychological 
effects. Most importantly, it would provide more reliable evidence for the interactions 
between the various substances of abuse. 
Future research investigating the set and setting of MDMA use should focus 
more on a wider range of factors influencing the drug-induced experience. Due to the 
complexity of the model, it is particularly important to investigate the interactions 
between different variables.  
Since this study provided some preliminary evidence that MDMA use is 
associated with increased insight and self-reflection, it is important to investigate this 
further, which may be best facilitated by a prospective research design to provide 
more robust data, to further contribute to understanding of whether MDMA can 
actually facilitate psychological insight. More importantly, future studies should take 
into account a range of settings of MDMA use, alongside personal predispositions. 
Further research should also focus more precisely on the risk factors associated with 
the abuse of MDMA. It is likely that the risk of drug abuse is associated with socio-
economic status and therefore future research studies should aim to recruit a more 
heterogeneous sample of MDMA users than the current study.  
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Conclusion 
This study adds to the existing literature supporting the relationship between 
various elements of the set and setting of MDMA use. It has provided preliminary 
explorations of the role of personality traits and emotional intelligence as well as 
motivation for drug use in shaping the effects of MDMA. The study also tentatively 
indicates that use of MDMA might be associated with some positive psychological 
outcomes, such as self-reflection and insight. At this stage, it is not possible to draw 
any definite conclusions, or to determine causality, however, it is important to 
consider a multifactorial model of interactions between a wide range of variables 
involving the set and setting of MDMA use. The results are consistent with the theory 
that MDMA has a potential for altering emotional experiences. Further research 
utilising a prospective design is warranted. 
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Appendix 1. Summaries of the studies included in the review 
Table 1  
Summaries of RCT trials: Psychological Effects of MDMA in Recreational Users.  
Authors/ 
Year 
Sample details Drugs administered Study Design Key Findings 
 
Baggott, 
Kirkpatrick, 
Bedi, & de 
Wit (2015)  
35 adults (66% male), with 
light-to-moderate ‘ecstasy’ 
experience, age: 18–35. 
 
USA 
 
MDMA1.5 mg/kg  
or placebo 
Two-session, within-subjects, randomised 
double-blind study. 
Participants completed a five-minute 
standardized talking task during which they 
discussed a personal relationship e.g. a friend 
or a family member.  
- MDMA increased use of social and sexual 
words, 
as well as words relating to both positive and 
negative emotions. 
 
Bedi, Hyman, 
& de Wit  
(2010) 
21 adults (57% male) with 
previous ‘ecstasy’ 
experience, age: 18-3 
MDMA 0.75 mg/kg 
, 1.5 mg/kg 
methamphetamine 20 mg,  
 double-blind, within-subjects randomized 
conditions four sessions: participants received 
MDMA methamphetamine and placebo.  
MDMA increased ‘empathogenic’ feelings, 
but accurate identification of threat-related 
signals in others was reduced. 
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USA 
placebo - self-report ratings of relevant affective states, 
and identified emotions from images of faces, 
pictures of eyes, and vocal cues.  
 Bedi, Phan, 
Angstadt, & 
de Wit  (2009) 
 
 
nine adults (78% male) age: 
18-29 with previous 
‘ecstasy’ experience   
 
USA 
MDMA 0.75 mg/kg,   
1.5 mg/kg, 
 placebo 
  three-session, within-participants, 
randomised double-blind design. 
Participants underwent fMRI
1
 while viewing 
standardized images depicting emotional 
facial expressions and completed self-report 
measures of sociability.  
MDMA increased self-reported sociability, 
and diminished responses to threatening 
stimuli but not to fearful facial expression. 
MDMA enhanced responses to rewarding 
social signals. 
Carhart-Harris 
et al. (2013) 
19 adults (74% male)  with 
previous  MDMA 
experience.  
 
UK 
100mg of MDMA-HCl,  
placebo 
two-session, within-participants, double- 
blind, randomised, placebo-controlled design.   
Participants underwent fMRI
1
 while they were 
probed to recall favourite and worst 
autobiographical memories.  
                                                                                                                                             
MDMA increased self-reported ratings of 
favourite memories as significantly more 
vivid, emotionally intense and positive. 
MDMA diminished the negative self-rating 
of worst memories.  
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Frye, Wardle, 
Norman, & de 
Wit (2014) 
36 adults (18 female), age: 
18-35 with light to moderate 
drug use.  
 
USA 
MDMA 0.75 mg/kg,   
1.5 mg/kg, 
 placebo 
three-session, randomised within-participants, 
double-blind design. 
Participants took part in a virtual social 
simulation task called “Cyberball” in which 
they experienced acceptance and rejection. 
Participants complete self-report measures of 
mood and self-esteem. 
MDMA decreased perceptions of rejection in 
a simulated social situation. 
Hysek, 
Domes, & 
Liechti (2012) 
48 adults (24 male) with 
limited or no previous 
experience of MDMA use. 
Age: 18-44 
 
Switzerland 
MDMA 125mg, 
placebo 
Two-session, randomised double-blind, 
placebo-controlled, within-subjects design.  
Participants completed self-reported measures 
of mood and subjective effects, and completed 
a task involved identification of complex 
emotions based on the eye region of faces.  
MDMA enhanced identification of mental 
state decoding for positive emotions, 
impaired mind reading for negative emotions 
and had no effect on mind reading for neutral 
stimuli (e.g., reflective).  
Hysek, 
Schmid, et al. 
(2014) 
32 adults (16 male) with 
limited or no previous 
experience of MDMA use.  
Age: 20-31.  
MDMA 125mg, 
placebo 
Two-session, randomised double-blind, 
placebo-controlled, cross-over design.  
Participants completed self-reported measures 
of mood and subjective effects, empathy, 
- MDMA increased explicit and implicit 
emotional empathy and pro-social behaviour 
in men.  
- MDMA did not increase cognitive empathy 
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Switzerland  
social behaviour measure, as well as 
completed tasks assessing cognitive and 
emotional aspects of empathy and facial 
emotion recognition.  
in women. 
- MDMA reduced the ability to identify 
negative emotions, including fear, anger and 
sadness, particularly in women.  
Hysek, 
Simmler, et al. 
(2014) 
16 adults (8 male) with 
limited or no previous 
experience of MDMA use. 
Age: M
3
=24.8, SD
4
=2.6 
 
Switzerland 
1. Placebo + placebo, 
2. Ritalin 60mg + placebo, 
3. Placebo + MDMA 
125mg, 
4. Ritalin 60mg + MDMA 
125mg 
 
Four-session, randomised double-blind, 
placebo-controlled, crossover design. 
Participants completed self-reported measures 
of mood and subjective effects, and completed 
facial emotion recognition task.   
- MDMA increased positive mood more than 
Ritalin.  
- Ritalin improved the recognition of sad and 
fearful faces while MDMA reduced the 
recognition of negative emotions.  
Kirkpatrick, 
Delton, 
Robertson, & 
de Wit (2015) 
Study 2: 32 adults (23 male) 
aged 18–30, who had used 
MDMA 4–80 times in their 
lifetime. 
 
USA 
MDMA 0.5 mg/kg, 1.0 
mg/kg and placebo 
Three-session, randomised double-blind, 
placebo-controlled, within-subjects design. 
Participants took part in a task measuring 
generosity where they make decisions about 
whether they or another person will receive 
money. 
MDMA produces pro-social effects such as 
generosity, but these appear to depend on the 
social proximity of the relationships. 
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Kirkpatrick & 
de Wit, (2015) 
32 adults (24 male) MDMA 
users, aged: 18-35 
 
USA 
1. MDMA 0.5 mg/kg 
2. MDMA 1.0 mg/kg 
3. placebo 
Three-session, randomised double-blind, 
placebo-controlled, mixed within- and 
between-subjects design. Participants were 
randomly assigned to one of three conditions: 
1. Solitary, 2. Research assistant present, 3. 
Other participant present. Participants 
completed subjective effects questionnaires 
and were video recorded to measure their 
social-interactions.  
The social contact reinforces some of the 
effects of MDMA.  
MDMA increased social interactions and 
ratings of the attractiveness of another person 
in the room.  
Kirkpatrick, 
Lee, Wardle, 
Jacob, & de 
Wit (2014) 
65 adults (40 male) with 
light-to-moderate past 
MDMA experience,  
aged: 18-35 
 
USA 
1. Placebo + placebo, 
2. Placebo + intranasal 
oxytocin 20 or 40 IU, 
3. MDMA 0.75 mg/kg + 
Placebo  
4. MDMA 1.5 mg/kg + 
placebo  
Four-session, randomised double-blind, 
placebo-controlled, within-subjects design. 
Participants completed measures of emotion 
recognition and sociability and subjective 
effects. 
MDMA impaired recognition of angry and 
fearful facial expressions, and the larger dose 
(1.5 mg/kg) increased desire to be with 
others, compared with placebo.  
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Kuypers et al. 
(2014) 
20 adults (12 male) poly-
drug MDMA users, aged 
between 18–26 years. 
 
Netherlands 
(1) pindolol + MDMA 
75mg + placebo;  
(2) placebo + MDMA 
75mg + placebo  
(3) placebo + placebo + 
oxytocin  
(4) placebo  + placebo + 
placebo.  
Four-session, randomised double-blind, 
placebo-controlled, within-subjects design. 
Participants completed tests measuring 
cognitive and emotional empathy and social 
interaction, defined as trust and reciprocity.  
MDMA selectively enhanced emotional 
empathy but did not increase cognitive 
empathy, trust and reciprocity.  
Wardle, 
Kirkpatrick, & 
de Wit (2014) 
101 adults (58 male) aged 
18-35 with light-to-
moderate past MDMA 
experience.  
 
USA 
MDMA 0.75mg/kg, and 
1.5 mg/kg,  
Placebo. 
Data from two studies using similar within-
subjects, double-blind randomised designs.  
Participants rated positive and negative 
responses to standardized positive, negative 
and neutral pictures with and without social 
content.  
MDMA increased positive ratings of positive 
social pictures, but reduced positive ratings 
of non-social positive pictures. The pro-
social effects of MDMA increase the value 
of social contact and closeness with others. 
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Table 2  
Summaries of naturalistic studies: Psychological Effects of MDMA in Recreational Users 
Authors/ 
Year 
Sample details Drugs administered Study Design Key Findings 
Hoshi, Bisla, 
& Curran 
(2004) 
16 ‘Ecstasy’ users (10 male) 
and 21 controls-other drugs 
users (6 male), age: 20-32.  
 
UK 
‘Ecstasy’ users took M 
=3.06, SD =1.12 ecstasy 
tablets on a day of drug 
use.  
An independent group, repeated measures 
design was used to compare ‘ecstasy’ users 
and non-drug users at two points in time: at 
the time of drug use in a club and four days 
later.  Participants completed measures of 
drug use, mood state, aggression, impulsivity 
and subjective effects of the drug, as well as a 
facial expression recognition task.  
- ‘Ecstasy’ users were better at recognising 
fearful facial expressions than controls at the 
time of drug use but less accurate than 
controls on day four.  
- fear recognition on day four was negatively 
correlated with number of years of ecstasy 
use and number of ecstasy tablets taken on 
one occasion.  
- ‘Ecstasy’ users scored lower on aggression 
scale than controls on day 0 and higher on 
day 4.  
Kamboj et al. 20 adults (7 men) with MDMA taken Two-session, naturalistic within-subjects MDMA increased self-compassion and 
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(2015) previous experience of 
MDMA use.  
Age: M=	25.50, SD= 3.59 
 
UK 
recreationally versus no 
drug. Dose and purity not 
determined.  
design. Participants completed MDMA-
related mood and symptoms measures, 
depression, attachment style and trait-self-
criticism scales. Self-criticism and self-
compassion scales were administered before 
and after ecstasy use and then after completing 
a guided compassionate imagery exercise.  
reduced self-criticism 
 
Higher attachment-related avoidance was 
associated with additive effects of 
compassionate imagery and ecstasy on self-
compassion.  
Stewart et al. 
(2014) 
39 adults: 17 ecstasy users 
(12 male, age M=22.76 
SD=3.17), 22 controls – non 
users (9 male, age M=23.00 
SD=5.28).  
 
UK 
MDMA taken 
recreationally versus no 
drug. Dose and purity not 
determined. 
An independent group, repeated measures 
design was used to compare ‘ecstasy’ users 
and non-drug users at two points in time: on 
the night of drug use and three days later.  
Participants rated the trustworthiness of 66 
faces, carried out three co-operative behaviour 
tasks and completed mood self-ratings. 
Ecstasy increased face trustworthiness and 
cooperative behaviour; on day 3 there were 
no group differences on any task.  
Trait empathy ratings were significantly 
higher in the ecstasy users 
Yip & Lee 
(2006) 
200 adults: 100 abstinent 
ecstasy users (50 male) and 
100 matched non-users.  
N/A Pseudo-experimental, between-subject non-
randomised design. 
Abstinent Ecstasy users were impaired on 
overall emotion recognition, in particular 
recognition of sadness and disgust.  
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Table 3 
Summaries of correlational studies: Psychological Effects of MDMA in Recreational Users 
Authors/ 
Year 
Sample details Drugs administered Study Design Key Findings 
Craig, Fisk, 
Montgomery, 
Murphy, & 
Wareing 
(2010) 
78 MDMA/polydrug 
users (35 female),  
38 cannabis only users 
(27 female), 
34 non-drug users (28 
female). 
 
UK 
N/A Retrospective correlational study, 
comparing MDMA polydrug users with 
cannabis users and non-users. Participants 
completed measures of drug use, EI
2
, 
mood and parenting styles and IQ 
measures.  
- ‘Ecstasy’-polydrug users did not differ 
from non-users on EI. 
- Adverse mood effects associated with 
ecstasy use were significantly related to 
lower EI.  
- Higher EI was significantly associated 
with ecstasy-related precautions used 
when taking this drug.  
Reay, 
Hamilton, 
30 adults:  15 polydrug 
‘ecstasy’ users (9 male, 
N/A Retrospective correlational study, 
comparing current ecstasy polydrug users, 
MDMA polydrug users scored 
significantly worse on social awareness 
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Kennedy, & 
Scholey 
(2006) 
age M=25 SD=5.8) and 
15 polydrug non-ecstasy 
user controls (7 male, age 
M=21.3 SD=5.8) 
 
UK 
with non-ecstasy plydrug-users. 
Participants completed s general drug use 
questionnaire, emotional intelligence 
scale, social intelligence scale.  
and social skills subscales of social 
intelligence scale. 
MDMA can impair social and emotional 
processing. 
ter Bogt, 
Engels, & 
Dubas (2006) 
265 non-hard drug using 
adults; 541 MDMA-
users, Aged: 18-27  
N/A Retrospective between participants 
correlational study. Participants 
completed a substance use questionnaire 
and personality traits measure assessing 
agreeableness, extraversion, 
conscientiousness, emotional stability, 
and openness.  
MDMA-using party visitors reported higher 
levels of extraversion and both MDMA and 
non-MDMA-using partygoers showed less 
conscientiousness.  
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Table 4  
Summaries of RCT trials: Psychological Effects of MDMA in a Therapeutic Setting.  
Authors/ 
Year 
Sample details Drugs administered Study Design Key Findings 
Bouso, 
Doblin, 
Farré, 
Alcázar, & 
Gómez-
Jarabo 
(2008) 
6 women with chronic 
and treatment resistant 
PTSD
5
 secondary to a 
sexual assault, aged 29-
49 with no previous 
experience with 
MDMA.  
 
 
Spain  
MDMA 50 mg and 
75mg, non-active 
placebo 
a double-blind, between-subjects, randomized and 
placebo-controlled within each dose condition. 
Participants had three psychotherapy sessions with 
two therapists (a man and a woman) before the 
MDMA experimental session and three sessions 
after the MDMA session.  
Participants completed measures of PTSD, anxiety 
and depression pre-, post-therapy and at a follow-
up. 
MDMA administered as an adjunct to 
psychotherapy were found to be safe. There 
were promising signs of efficacy and 
reduced PTSD symptomatology.  
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Oehen, 
Traber, 
Widmer, & 
Schnyder 
(2013) 
12 participants (10 
females)  with chronic 
and treatment resistant 
PTSD. Mean age = 41.4 
 
  
Switzerland 
MDMA 125 mg, plus 
62.5 mg 
supplemental dose 
Active placebo  
MDMA low dose 25 
mg, plus 12.5 mg 
supplemental dose 
randomized, double-blind, between-subjects active-
placebo controlled trial. Participants had	three 
MDMA experimental sessions, combined with 
weekly non-drug psychotherapy sessions. 
Participants completed PTSD scales	at baseline, 
three weeks after the second and third MDMA 
session, and at the 2-month and 1-year follow-ups. 
There was no statistically significant 
reductions in clinician rated PTSD scores, 
but there was clinically and statistically 
significant self-reported improvement. 
Clinician rated scores improved at the 1-
year follow-up. There were no drug-related 
serious adverse events. 	 
Mithoefer, 
Wagner, 
Mithoefer, 
Jerome, & 
Doblin 
(2011) 
and 
Mithoefer et 
al. (2013) 
20 adults (17 females) 
with chronic and 
treatment resistant 
PTSD
5
 secondary to a 
sexual assault, mean age 
40. 
 
USA 
MDMA 125mg and 
optional 
supplementary dose 
of 62.5mg, non-
active placebo.  
a double-blind, between-subjects, randomized and 
placebo-controlled. Participants had two 
preparatory psychotherapy sessions and received 
two MDMA experimental sessions, and integrative 
follow-up non-drug psychotherapy in-between 
MDMA sessions. Participants completed measures 
of PTSD, anxiety and depression pre-, post-therapy 
and at a follow-up. 
The rate of clinical response was 10/12 
(83%) in the MDMA group in comparison 
to 2/8 (25%) in the placebo group. There 
were no drug-related serious adverse 
events. 	The gains were maintained by the 
large majority of the participants between 
17 to 74 months after the original study. 
Only two participants relapsed.  
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Appendix 2. Additional data from the analysis 
Table 5 
Cronbach’s Alpha levels of internal consistency 
Self-Reflection and Insight Scale – Full SRIS α .841 
SRIS: Engaging in self-reflection  α .859 
SRIS: Need for self-reflection  α .856 
SRIS: Insight  α .702 
Trait Emotional Intelligence Questionnaire-Short Form (TEIQ-SF)  α .914 
The NEO Five-Factor Inventory (NEO-FFI) Full Scale  α .642 
NEO-FFI: Neuroticism  α .908 
NEO-FFI: Extraversion α .820 
NEO-FFI: Openness to Experience  α		.744 
NEO-FFI: Agreeableness α		.720 
NEO-FFI: Conscientiousness α		.856 
Substance Dependence Scale- Ecstasy (SDS)  α		.760 
SDS- MDMA α		.755 
Negative Effects Scale α		.703 
Positive Effects Scale (PES) α		.878 
PES: Energy α		.878 
PES: Euphoria α		.819 
PES: Self-insight α		.977 
PES: Sociability α		.886 
PES: Sexiness α		.918 
PES: Coping α		.846	
PES: Conformism α		.751	
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Table 6  
Demographic variables  
	 MDMA	Group	
n					%	
	
Comparison	group	
n						%	
	
Total	
n						%	
Relationship	status	
Single	
	
64			40.8%	
	
40			29.8%	
	
104			35.3%	
In	a	relationship	 66			42%	 56			40.6%	 122			41.4%	
Engaged	 5			3.2%	 8			5.8%	 13					4.4%	
Married	 10			6.4%	 28			20.3%	 38				12.9%	
Widowed	 1				0.6%	 0			0%	 1					0.3%	
Divorced	 2			1.3%	 1			0.7%	 3			1%	
Civil	union	 4			1.3%	 0			0%	 4			1.4%	
Domestic	partnership	 5			3.2%	 5			3.6%	 10			3.4%	
Total	 157			100%	 138			100%	 295			100%	
Employment		
Employed	for	wages	
Self-employed	
Looking	for	work	
Not	looking	for	work	
A	homemaker	
A	student	
Retired	
Unable	to	work	
Total	
	
69			43.7%	
	
93			67.4%	
	
162			54.7%	
29			18.4%	 11			8.0%	 40			13.5%	
14			8.9%	 8			5.8%	 22			7.4%	
5			3.2%	 4			2.9%	 9			3.0%	
2			1.3%	 3			2.2%	 5			1.7%	
36			22.8%	 17			12.3%	 53			17.9%	
2			1.3%	 2			1.4%	 4			1.4%	
1			0.6%	 0			0%	 1			0.3%	
158			100%	 138			100%	 296			100%	
Education	 	 	 	
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12th	grade	or	less	 6			3.8%	 1			0.3%	 7			2.4%	
High	school	graduate	 15			9.5%	 6			4.3%	 21			7.1%	
Some	years	of	college,		
no	degree	
36			22.8%	 19			13.7%	 55			18.6%	
Associate	degree	 5			3.2%	 1			0.7%	 6			2.0%	
Bachelor’s	degree	 54			34.2%	 44			31.9%	 98			33.1%	
Master’s	degree	 28			17.7%	 50			36.2%	 78			26.4%	
Professional	degree	 8			5.1%	 7			5.1%	 15			5.1%	
Doctorate	degree	 6			3.8%	 10			7.2%	 16			5.4%	
Total	 158			100%	 138			100%	 296			100%	
 
Histograms: Age  
MDMA	Group	
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	 Comparison	group	
	
	
Table 7 
The setting of MDMA use 
 
	
 
 
 
 
 
The	setting	of	MDMA	use	 n	 M	 SD	
At	home	with	friends/partner	 157	 33.23	 29.960	
At	home	on	my	own	 157	 3.55	 11.191	
Clubbing	 158	 31.46	 27.643	
Music	festival	 157	 18.99	 21.599	
Psychotherapy	session	 158	 0.82	 6.178	
Other	 158	 4.21	 14.140	
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Table 8 
Substance Dependence Scale: scores 
SDS MDMA Score Frequency Percent Valid Percent 
Cumulative 
Percent 
Original data Valid .00 100 63.3 66.7 66.7 
1.00 27 17.1 18.0 84.7 
2.00 10 6.3 6.7 91.3 
3.00 5 3.2 3.3 94.7 
4.00 2 1.3 1.3 96.0 
5.00 3 1.9 2.0 98.0 
6.00 2 1.3 1.3 99.3 
11.00 1 .6 .7 100.0 
Total 150 94.9 100.0 
 
Missing System 8 5.1 
  
Total 158 100.0 
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Appendix 3. Ethics Materials 
Research Review Panel Approval Letter 
This has been removed from the electronic copy.  
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Ethics Panel Approval Letter 
	
This has been removed from the electronic copy.  
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Participants Information Sheet and Consent form  
 
	
Psychological effects of MDMA (3,4-methylenedioxmethamphetamine): the function of the drug, 
set and setting. 
  
  
Hi, my name is Monika Wieliczko and I am a trainee clinical psychologist at Canterbury Christ 
Church University in the UK.  I am conducting research investigating a range of psychological 
and social factors that might influence the effects of MDMA on humans. 
  
Before you decide to take part in this study, it is important for you to understand why the 
research is being done and what it would involve. Please take time to read the following 
information carefully. 
  
Background 
The broad aim of this project is to look at factors influencing drug experience, including 
individual and social aspects. The study focuses on both positive and negative psychological 
effects resulting from MDMA as well as risk reduction factors among polydrug 
users.  Understanding the role of personality and motivation to drug use as well as the wider 
context of the environment in which intoxication occurs, might help us understand why the 
effects of the drug differ among people. 
   
Procedures 
Participation in the study is entirely voluntary. It is up to you to decide whether or not to do this.  If you 
do decide to take part, I would ask you to sign a consent form.  However, you are free to withdraw from 
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the study at any time. 
  
  
If you decide to take part in this study, I will ask you to abstain from  taking drugs for 7 days prior to 
the study to make sure you are not under the influence of any substances while participating in the 
study. 
You will be asked to complete an online survey. Items in the survey cover topics related to your pattern 
of MDMA and/or other drugs use, and the effects of the drugs. You would be also asked to 
complete questionnaires measuring a range of psychological traits. The whole process would 
take approximately 20-30 minutes.  
  
Data Storage, Retention, Destruction and Future Use 
All data collected in this study will be anonymised. Upon completion of the survey you will be 
asked to give consent to include your data in further analyses by pressing ‘send’ button. You 
are free to withdraw your data from the study at that point. Once you have given consent and 
pressed ‘send’, we cannot withdraw your data at a later stage because of the anonymised 
nature of the study. 
Electronic data will be stored in a secure data file for a minimum of 10 years and shredded 
after data collection and entry is complete. 
  
Ethical Issues 
The questions in the survey may influence the way you feel about taking drugs in general, 
either in a positive or negative way, or may have no effect. Please discuss any concerns you 
might have with Monika Wieliczko, at any point during the research process. 
  
Result Reporting 
The survey data will be analysed and written up as academic research. The data will be 
anonymous. A short report of the main findings will be made available to you if you request it 
by contacting me directly. 
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If you have any questions at any time about the study, please do not hesitate to contact 
Monika Wieliczko m.j.wieliczko@gmail.com 
  
	
CONSENT	FORM	
 
 
1. I confirm that I have read and understand the information 
sheet for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving any reason. 
 
3.  I understand that any information given by me may be used in 
future reports, articles or presentations by the research team. 
	
4.  I understand that my name will not appear in any reports, 
articles or presentations. 
 
5. I agree to take part in the above study. 
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Letter to ethics committee 
Dear Ethics Committee, 
 
I write to update you on the progress of my research project ‘Psychological effects of 
MDMA (3,4-methylenedioxmethamphetamine): the function of the drug, set and 
setting.’ 
I include a summary of the study and research findings. A similar summary has 
been distributed among those participants who requested information about the 
results. 
I am planning to disseminate the findings in a number of ways. The paper will be 
submitted to a peer-reviewed journal for publication. I will be also presenting my 
results at the Interdisciplinary Conference on Psychedelic Research in June 2016 in 
Amsterdam.   
If you wish to receive a copy of the paper following publication please let me know. 
Feel free to contact me with any outstanding queries related to the project. 
 
Kind regards 
 
Monika Wieliczko 
Trainee Clinical Psychologist 
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Research Summary for Ethics Committee 
	
Psychological effects of MDMA (3,4-methylenedioxmethamphetamine): the 
function of the drug, set and setting. 
 
Aims 
Zinberg's Interaction Model implies that the content of a drug-induced experience is a 
function of the pharmacological properties of the drug, the set (the user’s 
characteristics e.g. motivation and personality), and the setting (the physical and 
social context). The current research investigated the function of the set and setting 
and their role in shaping the psychological effects of 3,4-
methylenedioxmethamphetamine (MDMA), as well as their role in reducing the risk 
of drug abuse.   
Methods 
An online survey was distributed among adult MDMA polydrug users (n = 158) and 
MDMA-naïve controls (alcohol, nicotine and cannabis users, n = 138). Participants 
answered questions regarding their pattern of drug use, their motivation for MDMA 
use and the setting (e.g. clubbing, home with friends), as well as the subjective effects 
of MDMA. Participants also completed a range of self-report measures of self-
reflection and insight, emotional intelligence, and personality, as well as a drug 
dependency measure.  
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Results 
MDMA users displayed higher levels of self-reflection and insight, openness to new 
experience and lower levels of neuroticism and conscientiousness, in comparison to 
non-MDMA users. The significant predictors of self-reflection and insight were 
openness, emotional intelligence, MDMA use, extraversion and neuroticism.  When 
the analysis was rerun only for the MDMA group, the significant predictors of self-
reflection and insight were openness, emotional intelligence and self-insight effects of 
MDMA. High levels of self-reported negative effects of MDMA were predictors of a 
problematic drug use.  
 
Conclusions 
These findings suggest that there might be a relationship between MDMA use and 
higher levels of self-reflection and insight; however, longitudinal studies are required 
to further investigate the causality of this relationship. The results add to existing 
evidence that MDMA has potential for altering emotional experiences.  
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Appendix 4. Questionnaires used in the study 
NEO-FFI 
This has been removed from the electronic copy.  
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Drug Use Questionnaire 
This has been removed from the electronic copy.  
PSYCHOLOGICAL EFFECTS OF MDMA 
 
 135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSYCHOLOGICAL EFFECTS OF MDMA 
 
 136 
Severity of Dependence Scale  
This has been removed from the electronic copy.  
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Trait Emotional Intelligence Questionnaire –Short Form 
This has been removed from the electronic copy.  
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Self Reflection and Insight Scale 
This has been removed from the electronic copy.  
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MDMA Motives Questionnaire 
This has been removed from the electronic copy.  
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Effects of MDMA use Questionnaire 
This has been removed from the electronic copy.  
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